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                    GENERAL INTRODUCTION
    During the past few decades, advances in molecular biology have brought us a
wide variety ofpeptide- and protein-based pharmaceuticals for treating various diseases
[1-3]. The contribution to the treatment ofdisease by these drugs is significant, and it is
thought that clinical development ofthese drugs will increase in the future. In contrast,
at present, these drugs are mainly administered through peripheral routes, such as
intravenous (i.v.) and subcutaneous (s.c.) injections, because the properties in the
intestinal tract of such biotechnology-based drugs limit their administration routes and
formulation designs (Fig. 1) [4-7]. Even insulin, one of the most widely prescribed
peptide drugs, has a restricted delivery route by s.c. injections. For instance, the
permeation of peptides and proteins administered via the oral route through the lipid
bilayer is extremely limited because of their hydrophilicity. Moreover, they cannot
permeate through the paracellular route that is the pathway for hydrophilic compounds
because of their molecular weights. In addition, orally administered peptides and
proteins are immediately degraded through the action of various enzymes such as
trypsin and aminopeptidase in the intestinal lumen and cytoplasm. AIthough such
properties of the intestinal epithelium are essential to protect its vital function from
exogenous pathogens, these often become a significant disadvantage for the intestinal
absorption of peptides and proteins [4-9]. However, patients find the oral forms of
therapeutic drugs more attractive than the injectable forms because oral forms are more
convenient and easier to use. To yield therapeutic activity, orally administered
biotherapeutic agents need to circumvent such enzymatic and permeation baniers ofthe
gastrointestinal tract to achieve sufficient absorption into the systematic circulation.
                                   1
Resistance of these drugs to enzymatic degradation was improved in part by strategies
such as protease or peptidase inhibitors [10-12] and carrier systems such as micro- and
nano-sized particles [13,14], liposomes [15-17], emulsions [18,19], and hydrogels
[20-22]. However, it is clear that there will be limited success from strategies directed at
overcoming the enzymatic barrier alone. Unless one can increase the membrane
permeability of therapeutic peptides and proteins, it is unlikely that high oral
bioavailability will be achieved [6]. Although there are some permeation enhancers that
facilitate the poor perrneation ofthese drugs through the epithelial membrane [1O,23,24],
advances in these reagents for clinical use are limited by mechanisms including the
disturbance of the epithelial lipid membrane and the opening of tight junctions, which
lead to the uptake of drugs plus pathogens and toxins into the circulation as the
intestinal epithelium functions as an essential banier to exogenous pathogens. A secure
strategy to improve the absorption of these drugs across the intestinal epithelial banier
is essential to achleve sufficient oral bioavailability to enable clinical use.
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Fig. 1. Inherent barriers to oral absorption oftherapeutic peptides and proteins in the gastrointestinal
tract. These barriers consist of enzymatic degradation in gastrointestinal lumen and intracellular
compartment, mucus layer lying on the microvillus, and lipid bilayer-based cell membrane.
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     Meanwhile, in recent decades it has been reported that the cell-penetrating
peptides (CPPs) including arginine-rich peptides such as human immunodeficiency
virus (HIV)-ITat (48-60) [25-30] and oligoarginine, an oligomer ofarginine (one ofthe
basic amino acids) containing six or more amino acids [25-28,3e,31] and amphipathic
peptides such as penetratin derived from the third helix ofthe Drosophila Antennapedia
homeodomain protein [32] (Table 1) can be efficiently introdueed into the intracellular
space via adsorption to cell-surface proteoglycans and subsequent endocytotic pathway
[33-39], especially macropinocytosis [40,41]. Moreover, the conjugation of CPPs with
poorly internalized macromolecules such as proteins [42,43] and nucleic acids [44],
antibodies [45], and drug-delivery carriers such as liposomes [34,46-48] promotes their
introduction into the cytoplasm and nucleus. CPPs can also translocate through the
membranes of numerous cells because of their low cell specificity. Therefore, CPPs
have frequently been employed as usefu1 tools for intracellular delivery of therapeutic
macromolecules. Although there is only limited information about their effects on the
membrane permeability of macromolecular drugs, one study reported that insulin
transport across Caco-2 cells was dramatically increased by conjugation of insulin with
Tat peptide [49]. Therefore, I speculated that peptide and protein drug absorption from
the intestine might be improved by using this behavior of CPPs. At present, however,
the CPP strategy research lacks sufficient numbers of in vivo studies to demonstrate
their therapeutic potential. In this study, I applied such ability of CPP to intestinal
delivery approach for therapeutic peptides and proteins.
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Table 1. Examples ofpeptide vectors for intracellular delivery [26]
Peptides Sequences
Basicpaptids
  HIV-1 Tat (48-60)
  Oligoarginine
Basio(antphiphthcpeptitles
  Antennapedia (43-58) Oenetratin)
  Model amphipathic peptide
Chimerapeptides
  Tiunsportan (galanin/mastoparan)
  Pep-1 (hydrophobicANLS)
Hydeophobicpeptitte
  Membrane translocating sequence peptide
GRKKRRQRRRPPQ
Rn (n=-7-11)
RQIKIVVFQNRRMKWKK
KIjALKLALKALKAAI.KLA-amide
GVVTLNSAG"YLLGKINLKALAALAKKIL
KETWWETwwTEWSQPKIKKRKV-cysteamine
AAVALLPAVLLALLP
A: Alanine, E: Glutamic acid, F: Phenylalanin, G: Glycine, I: Isoleucine, K: Lysine, L: Leucine,
M: Methionine, N: Asparagine, P: Proline, Q: Glutamine, R: Arginine, S: Serine, T: Threonine, V:
Valine,W: Tryptophan, Y: Tyrosine.
     In Chapter 1, I evaluated whether CPPs can improve intestinal absorption of
macromolecular drugs and compounds in rats. As shown in Fig. 2, the coadministration
of CPP with macromolecular drug and the administration of CPP-drug conjugate are
considered as the strategies using CPP to enhance their intestinal absorption. ln this
chapter, I evaluated the effect of oligoarginine, typical CPP, on the intestinal absorption
of insulin, interferon B (IFN-B) and fiuorescein isothiocyanate-labeled dextran 4,400
(FD-4) after coadministration of oligoarginine which is more convenient approach.
Furthermore, I examined whether oligoarginine has the unfavorable effect to intestinal
mucosal membrane for safe use of oligoarginine. In addition, I evaluated the effect of
chain length of oligoarginine on the improvement of intestinal drug absorption by
coadministration of oligoarginine. ln Chapter 2, to find out the more effective and safer
CPP on the improvement of intestinal insulin absorption, I screened the ability of
various CPP such as oligoarginine and penetratin to enhance the intestinal insulin
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absorption. In Chapters 3 and 4, I examined the mechanisms underlying the
improvement of intestinal drug absorption by coadministration of CPP. in Chapter 3, I
evaluated the permeation characteristics of oligoarginine through intestinai epithelial
membrane. Furthermore, I also evaluated the intestinal absorption of fusogenic
leuprolide which is conjugated with oligoarginine to examine the potential of another
approach in which conjugate of drug and CPP was used as shown in Fig. 2 (a). In
Chapter 4, I QIarified the importance of intermolecular interaction between drug and
CPP on the improvement ofintestinal drug absorption by coadministration ofCPP.
        (a) CPP - Drug
              lntestinal tract [ntestinal epithelium Btood stream
Fig. 2. Schematic illustration of CPP-based intestinal delivery strategy for therapeutic peptides and
proteins. (a) Conjugation ofpeptides/proteins with CPP, (b) Physical mixtui'e of peptideslproteins
and CPP.
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1. Introduetion
    It is clear that strategies directed at overcoming the enzymatic barrier alone will
have only limited success in the development oforal forms ofpeptide and protein drugs.
High oral bioavailability is unlikely to be achieved unless one can increase the
membrane permeability of macromolecules. Recent reports using CPPs indicate that
drugs that are poorly permeable through the cell membrane can be taken up efficiently
by diverse cells without altering drug activity [25--27]. Therefore, I speculated that
peptide and protein drug absorption from the intestine might be improved by using this
behavior of CPPs.
    In this chapter, I evaluated whether CPPs can improve intestinal absorption of
insulin in rats. The effect ofCPPs on macromolecular intestinal absorption was further
examined using IFN-B and FD-4 macromolecules as model macromolecular solutes.
Peptides oomposed of six (R6), eight (R8), and 10 (RlO) residues of arginine were used
as the CPP. To assess the safety ofCPP in the intestinal epithelium, I also measured the
Ieakage of lactate dehydrogenase (LDH), an intraoellular enzyme inherent in the
enterocyte ofthe intestinal epithelium, and performed light microscopic observation of
intestinal tissues after pretreatment with oligoarginine.
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2. Materials and methods
2.1. Materials
    Recombinant human insulin (26 IU!mg), 200/o formalin neutral buffer solution, and
LDH Test Wako were purchased from Wako Pure Chemical Industries, Ltd. (Osaka,
Japan). L-R6 (RRRRRR, R: L-arginine), D-R6 (rrrrrr, r: D-arginine), D-R8 (rrrrrrrr),
D-RIO (rrrrrrrrrr), FD-4, and sodium taurodeoxycholate were purchased from
Sigma-Aldrich Co. (St. Louis, MO, USA). IFN-B (O.6 Å~ 107 IUIvial) was kindly
supplied by Toray Industries, Inc. (Kanagawa, Japan). All other chemicals were of
analytical grade and commercially available.
22. Preparation of drug and oligoarginine solution
    Specific amounts of recombinant human insulin were dissolved in 50 pL of O.1 M
HCI in polypropylene tubes. The insulin solution was diluted with 2.4 mL of
phosphate-buffered saline (PBS, pH 7.4) containing O.OOIO/o methylcellulose, which
prevents the adsorption ofinsulin on the tube surface, and normalized with 50 pL ofO.1
M NaOH. The FD-4 solution was prepared at 2 mglmL, and the IFN-B solution at O.9 Å~
106 IUImL, in PBS. Specific amounts of L-R6, D-R6, D-R8, or D-RIO was measured in
the polypropylene tubes, and an aliquot of drug solution was added to the tubes and
mixed gently to yield a clear solution.
2.3. In situ loop absorption study
    This research was performed at Hoshi University and complied with the
regulations of the Committee on Ethics in the Care and Use of Laboratory Animals.
Male Sprague Dawley rats weighing 180-220 g were purchased from Tokyo Laboratory
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Animals Science Co., Ltd. (Tokyo, Japan). Animals were housed in rooms controlled
between 23 Å} 1 OC and 55 Å} 50/o relative humidity, and they had free access to water and
food during acclimatization. Animals were fasted for 24 h before the experiments.
Following anesthetization by intraperitoneal (i.p.) injection of sodium pentobarbital (50
mg/kg; Dainippon Sumitomo Pharm Co., Ltd., Osaka, Japan), rats were restrained in a
supine position on a thermostatically controlled board at 37 OC. Additional i.p.
injections of sodium pentobarbital (12.5 mglkg) were used every 1 h to maintain the
anesthesia.
    The ileum was exposed following a small midline incision made carefu11y in the
abdomen, and its proximal-to-ileocecal junction segments (length = 10 cm) were
cannulated at both ends using polypropylene tubing. These were ligated securely to
prevent fluid loss and retumed carefu11y to their original location inside the peritoneal
cavity. To wash the intestinal content, PBS warrned at 37 OC was circulated through the
cannula at 5.0 mLlmin for 8 min using an infusion pump (KD Scientific Inc., Holliston,
MA, USA). The cannulation tubing was removed and the segments were then closed
tightly; about 1 mL ofperfusion solution remained in the segments. Rats were left on
the board at 37 OC for a further 30 min to recover from the elevated blood glucose
concentration resulting from the surgery described above. After the 30 min rest, O.5 mL
of drug-oligoarginine mixed solution or drug solution (control) was administered
directly into the 6 cm ileal loop made from the 10 cm pretreated segment. The doses
were 50 IU/kg body weight for insulin, 5 mgfkg for FD-4, and 2.25 Å~ 106 IU/kg for
IFN•-B. For evaluating the effect of L- and D-R6 on insulin intestinal absorption, the
doses of oligoarginines were 6.25, 12.5, and 25.0 mg/kg body weight. For evaluating
the effect of chain Iength of oligoarginine on insulin intestinal absorption, the doses of
9
D-R6, D-R8 and D-RIO were 6.25, 8.3 and 10.35 mglkg, respectively, and the molar
concentration ofthese administration solutions was the same (2.6 mM).
    The relative bioavailability ofenterally administered insulin was calculated relative
to the s.c. route. Briefly, an insulin solution was prepared by dissolving an appropriate
amount ofrecombinant human insulin in PBS at an s.c. dose of 1.0 IUlkg body weight.
To maintain the same physical conditions for the rats, the same surgery (ileal loop) was
performed on animals receiving s.c. insulin as on rats in the intestinal absorption study.
    During the experiment, a O.25 mL blood aliquot was taken from the jugular vein
before and 5, 10, 15, 30, 60, 120, 180, and 240 min after dosing. Tuberculin syringes (1
mL) were preheparinized in the usual fashion by coating the syringe wall with
aspirating heparin and then expelling all heparin by depressing the plunger to the needle
hub. Plasma was separated by centrifugation at 13,OOO rpm (13,400 Å~ g) for 1 min.
Blood glucose concentration was measured with a glucose meter (Novo Assist Plus,
Novo Nordisk Pharma Ltd., Tokyo, Japan) in the insulin studies and used to represent
the biological activity of insulin. The biological activity of insulin is expressed as a
percentage of the predose glucose concentration adjusted to the corresponding blood
glucose concentration in the control group (insulin solution). The magnitude of the
hypoglycemic response was calculated using the trapezoidal method as the area above
the curve (AAC) for O-4 h. The plasma insulin concentration was determined using an
enzyme immunoassay (Insulin ICMA kit, Molecular Light Technology, Wales, UK).
The total area under the insulin concentration curve (AUC) from 04 h was estimated
from the sum of successive trapezoids between each data point. The bioavailability was
calculated relative to the s.c. injection as described above. The peak plasma
concentration (C.,.) and the time taken to reach the peak plasma concentration (Tm..)
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were deterfnined from the plasma insulin concentration-time curve. Plasma IFN-B
concentration was determined using an enzyme immunoassay (IFN-6 ELISA kit, ToraY
Industries, Inc., Kanagawa, Japan). Plasma FD-4 concentration was determined using a
microplate luminometer (Mithras LB940, Berthold Japan, Tokyo, Japan) at excitatiOn
and emission wavelengths of485 and 535 nm, respectively.
2.4. LDH leakage
     LDH leakage from the intestinal membrane, one of the indices of toxicitY
assessment, was measured after incubation with Cpp for a predetermined time• The 6
cm ileal loop made from the 10 cm pretreated segment, as described above, was used
for these experiments. The ileum was treated with 20 mL of PBS warmed to 37 OC and
then flushed out with air. A solution of O.5 mL PBS, 10/o (wlv) sodium
taurodeoxycholate, L-R6 (25.0 mgZkg), or D-R6 (25.0 mglkg) was administered to the
ileum and left in the ileal segments for 2 h. After the 2 h incubation, the ileal loop WaS
washed with 3 mL PBS and the intestinal fluid was collected. The concentration of LDH
in the fluid was determined using the LDH Test Wako (Wako Pure Chemical IndustrieS,
Ltd., Osaka, Japan).
2.5. Light microscopy
    The ilcal segments were removed following the 4 h in situ absorption study and
fixed with 200/o formalin neutral buffer solution. Thin cross-sectional samples were
prepared on a microtome and stained with hematoxylin and eosin for light microsCOPiC
observation to histologically assess tissue damage.
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2.6. Statistical analysis
    Each value is expressed as the mean Å} standard error (S.E.) of 3-8 determinations.
For group comparisons, analysis of variance (ANOVA) with a one-way layout was
applied. The mean values were evaluated by Student's unpaired t test and p Åq O.05 was
considered significant.
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3. Results
3.1. Effect of oligoarginine on insulin absorption from the ileum
    Figures 3 and 4 show the effect of L-R6 and D-R6 on the ileal insulin absorption
(A) and resultant hypoglycemic effect (B). No apparent hypoglycemic response was
observed following administration of insulin solution, demonstrating no insulin
absorption from the ileal segments. In contrast, coadministration of oligoarginine in a
dose-dependent manner increased insulin absorption. As shown in Fig. 4, insulin
absorption increased more after treatment with D-R6 than after treatment with L-R6,
implying that the more metabolically stable oligoarginine induced the bigger insulin
absorption from the ileum.
    Table 2 summarizes the pharmacokinetic parameters derived from the insulin
concentration-time profiles following in situ administration of insulin with
oligoarginine to the ileal segments. AUC is derived from the plasma insulin
concentration-time profile, and the area AAC is derived from the blood glucose
concentration-time profile. The relative bioavailability (BA) and pharmacological
availability (PA) were calculated from data obtained in the s.c. injection study. Although
negligible absorption was observed with administration of the insulin solution, L-R6 and
D-R6 significantly increased C.., AAC, AUC, PA, and BA, which are all related to the
extent of absorption. Significant linear relationships resulted after plotting AUC (r ==
O.721,pÅq O.Ol) and AAC (r = O.619,p Åq O.Ol) ofthe insulin vs. dose response to L-R6.
Similar patterns were observed for AUC (r = O.8328, p Åq O.Ol) and AAC (r = O.9074,p
Åq O.Ol) ofthe insulin vs. dose response to D-R6.
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Table 2. Pharmacokinetic parameters following in
doses ofL- or D-R6 into the ileal segments
situ administration of insulin with varlous
 Crmax
(pUlmL)
Trnax
(min)
    AAC
{Ole glu. redua 'hr)
  AUC
(pU'hr/mL)
PA
(Ole)
BA
(o!o)
Insulin solutien
+ L.R6
   6.Z5 mgtkg
   12.5 mgtng
   25.0 mgtkg
+ D-R6
   6.25 mgtng
   12.5 mgtkg
   25.0 mgtkg
16.9 Å} 4.6
24.0 Å} 12.6
64.1Å} 9.1set
141.5 Å} 27.8*
116.1 Å} 5Z3
208.4 Å} 623
395.6 Å} 104.8S
10.0 Å} 2.9
10.0Å} 2.9
43.3 Å} 16.7
25.0 Å} 82
20.0 Å} 5.8
33.8Å}9.4
37.5Å} 7.5t
1.6Å} O.9
O.2Å} O.2
15.7Å} 10.9
37.9Å} 12.0*
54.5Å} 18.2
94.8 Å} 37.7
214.7Å}20.4tde
12.6Å}3.5
10.1 Å} 2.2
65.5Å} 19.l
96.7 Å} 22.2"
120.9Å}42.4
1ss.8Å}27S**
464.0 Å} IW.lt
O.1 Å} O.O
g.o Å} o.o
O.7Å} O.5
1.7Å} O.5*
2.4 Å} O.8
42Å} 1.7
9.5 Å} ostt
O.4 Å} O.1
O.3 Å} O.1
Z.2 Å} O.6
3.3 Å} O.7"
4.1 Å} 1.4
6.7Å}O.9tsu
15.7 Å} 3.7*
Data: mean Å} S.E. (n=3-8).
Cmax, the maximum conoentration; T,..., the time to reach the C...; AAC, the area above the
curve; AUC, the area under the curve; PA, pharmacological availability compared with s.c.; BA,
relative bioavailability compared with s.c.
"pÅqO.05, ""pÅqO.O1, significant difference compared with the corresponding "insulin solution".
3.2. Effect of oligoarginine on IFN-B and FD-4 absorption from the ileum
    Table 3 shows the effect ofoligoarginine on the intestinal absorption ofthe protein
drug, IFN-B. Although the same dose of L-R6 (25.0 mglkg) significantly inoreased the
ileal absorption of insulin (Fig. 3 and Table 2), the ileal absorption of IFN-B did not
increase in the presence of L-R6. Similarly, neither L-R6 nor D-R6 (25.0 mg/lcg)
increased the ileal absorption of FD-4, which is representative of hydrophilic
macromolecules (Table 4).
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Table 3. Pharrnacokinetic parameters following in situ administration
of IFN-6 with L-R6 into the ileal segments
 Cmax
(IUImL)
Tmax
(min)
  AUC
([U ' hr/m L)
IFN-P solution
IFN-P + L-R6
10.0 Å} 4.1
 6.4 Å} 1.2
103.8 Å} 53.8
 50.0 Å} 10.0
39.2 Å} 17.1
11.9Å}3.8
Dose ofL-R6: 25.0 mg/kg.
Data: mean Å} S.E. (n=3--6).
Crna., the maximum concentration; T...,
the area under the curve.
the time to reach the C.,.; AUC,
Table 4. Pharmacokinetic parameters following in situ administration
ofFD-4 with L- or D-R6 into the ileal segments
 Cmax
(l.tg/mL)
Tmax
(min)
  AUC
(ptg t hrfmL)
D-4 solution
FD-4 + IrR6
FD-4 + D-R6
O.3 Å} O.1
O.6 Å} 02
O.7 Å} O.2
105.0 Å} 90.0
 40.0 Å} 17.3
12e.o Å} 6o.o
O.8 Å} O.9
1.2 Å} 1.1
2.0 Å} 1.1
Dose ofL- or D-R6: 25.0 mglkg.
Data: mean Å} S.E. (n=3--4).
C.,., the maximum concentration; T.,.,
AUC, the area under the curve.
the time to reach the C nvax;
3.3. Effeet of chain length of oligoarginine on insulin absorption from the ileum
    Insulin was coadministered with oligoarginine composed of six, eight, or 10
arginine residues (6.25, 8.3 or 10.35 mg/kg, respectively) to the ileum, and their effects
on insulin absorption were compared (Fig. 5). As shown in Fig. 5, D-R8 and D-RIO
enhanced insulin absorption from the intestine more markedly than did D-R6. Table 5
summarizes the pharmacokinetic parameters derived from the insulin
concentration-time profiles shown in Fig. 5. D-R8 caused the greatest increase in
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intestinal insulin absorption. Compared with D•-R6, D-R8 had 3.4-times higher relative
BA and D-RlO had 2.7-times higher relative BA for insulin.
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Fig. 5. Plasma insulin (a) and blood glucose (b) concentration vs. time profiles follovving in situ
administration of insulin (50 IUIkg) with D-R6 (6.25 mg!kg), D-R8 (8.3 mglkg) or D-RIO (10.35
mglkg) into the ileal segments. Each data point represents the mean Å} S.E. (n=3-8). Key: (O)
insulin PBS solution (control); (e)D-R6; (1)D-R8; (A)D-RIO.
Table 5. Pharmacokinetic parameters following in situ administration of insulin with D-R6, D-R8,
and D-RlO into the ileal segrnents
 Cmaz
(ptUfmh)
Tmax
(min)     AAC AUC(O/o gluredua'hr) (pU'hrlmL) PA(e/e) BA(O/e)
Insulin solution
+ D.R6
+ D-R8
+ D-RIO
 16.9Å}4.6 10.0Å}2S
116.1Å}523 20.eÅ}5S
384.0Å}115.9 45.0Å}8.7t
238.4Å}49.3* 30.0Å}O.O
 1.6 Å} O.1
 54.5 Å} 18.2
222.8 Å} 438*
 99.7Å}41.8
 12.6Å}35 O.1Å}O.O O.4Å}O.1
120.9Å}42.4 2.4Å}O,8 4.1Å}1.4
417.7Å}122.1* 9.9Å}1,9t 14.1Å}4.1*
322.9Å}106.9 4.4Å}1.9 10SÅ}3.6
Doses of D-R6, D-R8, and D-RIO: 6.25, 8.3 and 10.35 mg!kg, respectively, and the rnolar
concentration ofthese administration solutions was the same (2.6 mM).
Data: mean Å} S.E. (n==3-8).
Crn.x, the maximum concentration; T,.ax, the time to reach the C.,.; AAC, the area above the curve;
AUC, the area under the curve; PA, pharmacological availability compared with s.c.; BA, relative
bioavailability compared with s.c.
'pÅqO.05, significant difference compared with the corresponding `Cinsulin solution".
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3.4. Biochemical and histological examinations of the ileal membranes following
oligoarginine administration
    Table 6 shows data on LDH leakage in the absence (PBS, control) or presence ofL-
or D-R6 (25.0 mglkg) in the ileal loop for 2 h. LDH leaked negligibly into the mucosal
side, and the LDH leakage was similar in the oligoarginine-treated segments and the
PBS-treated segments. In contrast, sodium taurodeoxycholate significantly increased
LDH leakage (4.26 vs. 1.19 U).
    Figure 6 shows light micrographs of the ileal mucosal membranes pretreated with
(a) PBS, (b) L-R6 12.5 mg/kg, (c) L-R6 25.0 mglkg, and (d) L-R6 37.5 mglkg for 4 h.
The micrographs (Fig. 6) show no apparent histological damage in the L-R6 -treated
mucosal membranes compared with the PBS-treated (control) membranes. These data
suggest that oligoarginine administration did not alter the ileal membrane integrity.
Table 6. Lactate dehydrogenase (LDH) leakage following PBS (control),
L-R6 (25.0mgZkg), D-R6 (25.0 mglkg) or 1 wlV9/o sodium taurodeoxycholate
pretreatment for 2 h
Preparation LDH leakage (U)
       Control
        L-R6
       D-R6
Sodium taurodeoxyeholate
1.19 Å} O.08
1.49 Å} O.11
1.55 Å} O,16
4.26 Å} O.89 de
Data: mean Å} S.E. (n=3-5).
*pÅqO.05 compared witih control.
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Fig. 6. Light micrographs of the ileal mucosal membranes following in situ administration of (a)
insulin-PBS solution, and (b) 12.5 mg!kg, (c) 25.0 mglkg, and (d) 37.5 mglkg of L-R6 with insulin
for 4 h. The bar indicates 100 ym. Tissues were stained with hematoxylin and eosin following
foration in 200/o forrnalin neutral buffer solution.
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4. Discllssion
    In the past decade, studies have indicated that CPPs enable the delivery ofdifferent
bioactive compounds and drug carriers by chemically hybridizing with target materials
[34,42,45,46]. The CPPs deliver their cargo into the cytoplasm by directly perturbing
the lipid bilayer structure ofthe cell membrane or by endocytosis [50,51]. CPPs appear
to have little or no toxic effects because penetration causes little disturbance to
membranes, and Tat appears to cause practicaily no harm to cell membranes [51,52].
Toxicity and undesirable side effects have not been detected in most in vivo applications
ofCPPs [42,51]. These methods are expected to become powerfu1 tools for overcoming
the low permeability ofpeptide and protein drugs through the epithelial cell membrane,
which is the greatest barrier to oral delivery of macromolecular drugs. Although
structural modification strategies using CPP may be usefu1, care must be taken not to
reduce the biological activity of these drugs. So far, there is little information about
whether intermolecular chemical conjugation is essential for a CPP's ability to induce
cells to take up macromolecules.
    To address these issues, I examined whether oligoarginine enhances the absorption
of intestinal bioactive macromolecular drugs without covalently binding to these
molecules. As shown in Fig. 3 and Table 2, L-R6 significantly enhanced intestinal
insulin absorption and induced a strong hypoglycemic effect in a dose-dependent
manner. More pronounced insulin absorption-enhancing effects were observed after
D-R6 coadministration with insulin (Fig. 4 and Table 2). To my knowledge, this is the
first demonstration that insulin intestinal absorption can be enhanced by a physical
mixture containing oligoarginines, and in particular, the D-form. Such mixture
preparations are more feasible for delivering protein and peptide drugs than conjugated
20
forms because they are unlikely to decrease the biological activity of the drug and
because they are easy to prepare. These CPP strategies are considered highly promising
for the development of an oral delivery system for insulin. In contrast, as shown in
Table 3, L-R6 had no enhancing effect on intestinal IFN-P absorption at a dose of25.0
mglkg, which was sufficient to increase intestinal absorption of insulin. These results
suggest that the ability of oligoarginine to increase intestinal absorption might differ
between peptide and protein drugs (molecular weight of insulin: ca. 5.8 kDa and IFN-B:
ca. 23 ld)a). Further study is needed using various macromolecules of different
molecular size and charge to clarify the usefulness ofCPPs as oral carriers for bioactive
macromolecules.
    The L- and D-oligorners of arginine have a similar ability to efiter into cells [31].
However, I found that the ability of L- and D-oligomers of arginine to increase
absorption differed dramatically in the small intestine. The reason for this difference
could be explained by the observation that peptides containing the L-form of amino
aeids are metabolically more unstable than those containing the D-form [53]. Thus, L-R6
may be degraded rapidly by peptidases that are highly active in the intestinal lumen.
    The number of arginines within a peptide sequence has an important infiuence on
the ability ofthat peptide to enter cells [27,31]. Futaki et al. [27] suggested that R6 and
R8 are internalized best by mouse macrophage RAW264.7 cells of peptides composed
of ZF16 residues of arginine. Incubation of Jurkat cells, a human T-cell line, with R15
resulted in more intensive internalization than other oligoarginines used [31]. Thus, one
may speculate that the extension of an arginine oligomer does not by itself increase the
degree of cellular uptake. I used in situ absorption experiments to evaluate the effect of
the length of oligoarginine on insulin absorption. The efficiency of enhancement of
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bioavailability differed markedly between D-R6, D-R8, and D-RIO; D-R8 enhanced
insulin mucosal absorption the most efficiently. These results suggest that there is an
optimum number of arginines for enhancing intestinal absorption of insulin (Fig. 5 and
Table 5). Although the reason why there is an optimal number of arginine residues
remains unknown, chain length is presumably associated with the degree of hydrogen
bonding with phospholipids, interactions with the cell surface proteoglycans, or
permeability of oligoarginine through the mucous layer. A more mechanistic study of
the translocation ofoligoarginine through cell membranes is required.
    I found that the difliisive absorption of macromolecular dextran, FD-4, was not
enhanced by coadministration with L- or D-R6 at a concentration (25.0 mglkg) sufficient
to increase insulin absorption (Table 2). Because FD-4 is a hydrophilic compound and a
marker of the paracellular pathway, these results exclude the possibility of involvement
of opening the paracellular pathway on the insulin absorption-enhancing effect of
oligoarginine. In addition, the microscopic observations together with the data on LDH
leakage show that the membrane integrity appears to remain undamaged (Fig. 6 and
Table 6). These data strongly suggest that the effect of oligoarginines on insulin
absorption were not caused by cellular damage.
    CPPs are thought to be taken up mainly by cell-mediated macropinocytosis [40,41]
through the interaction between the positive charge derived from arginine residues and
the negative charge derived from proteoglycans on the cell surface [33-37]. Therefore, I
hypothesized that this proposed mechanism could explain how the molecular complex
of the drug and oligoarginine is introduced into epithelial cells. I found that
oligoarginine enhanced the intestinal absorption of insulin but did not enhance the
absorption of other macromolecules such as IFN-B and FD-4. lnsulin has a negative
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charge in neutral conditions, and insulin may associate with oligoarginine
electrostatically. If so, these molecular complexes could be taken up by the interaction
between oligoarginine and the surface of epithelial cells. In contrast, IFN-B has a
relatively positive charge in neutral conditions, which may set up a repulsive force or
prevent intermolecular interaction with oligoarginine. Similarly, noncharged
macromolecules, such as FD-4, may not interact with positively charged oligoarginine.
A more complete understanding of the mechanisms involved in the CPP-induced
enhancement of insulin absorption through the intestinal membrane is needed.
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5. Conclusions
    I have demonstrated that intestinal insulin absorption is enhanced markedly
without causing detectable damage in cellular integrity by coadministration of insulin
with oligoarginine, but absorption of IFN-B and FD-4 was not enhanced by
oligoarginine. The increase in absorption by oligoarginine occurred without chemical
hybridization between oligoarginine and insulin. The detailed mechanism responsible
for the ability of oligoarginine to increase insulin absorption remains unclear. To
develop a macromolecular oral delivery system using oligoarginine, more data on its
efficacy and safety and the underlying mechanism are needed.
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                    Chapter 2
Usefulness ofvarious cell-penetrating peptides to improve
            intestinal insulin absorption
25
1. Introduction
     In the last chapter, I have demonstrated that oligoarginine known as CPP exerts a
significant enhancing effect on intestinal insulin absorption without any untoward
effects on the intestinal mucosa. CPPs are peptides that have characteristics that enable
them to be readily taken up by several types of cells as well as the ability to bring
various substances into the cytoplasm via intermolecular conjugation [34,42-48].
However, I found that an increase in intestinal insulin absorption by oligoarginine
occurred without covalent binding between oligoarginine and insulin. This approach has
the advantage ofnot requiring the oomplicated molecular structure modification process
for chemical conjugation and thus the loss ofbiological activity ofpeptides and proteins
through conjugation.
     Oligoarginine could significantly improve the intestinal absorption of insulin;
however, this requires relatively high doses ofthe CPP. Such a high dose ofR6 does not
show any untoward effects on the intestinal mucosa following administration of a single
dose. However, the safety risks involved in the administration of multiple doses and the
product cost in actual clinical development mean that safer and more effective CPPs are
required to improve the intestinal absorption of various therapeutic peptides and
proteins. Therefore, the present study aimed to identify such a CPP for improving the
intestinal absorption ofbiodrugs. Ten different CPPs were selected based on a literature
search (Table 7), and their ability to enhance the intestinal bioavailability of insulin was
evaluated by the in situ ileal absorption method in rats. In addition, because the
absorption enhancing ability of the CPPs depends on the stereoisomeric difference of
the peptides as shown in Chapter 1, the effects of the L- and D-forms of CPPs on ileal
insulin absorption were compared.
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Table 7. iiniino acid sequences ofcell-penetrating peptides used in this study
Peptides Sequence
Arginine rieh peptides
 Arginine octamer (R8)
 Arginine dodecamer (R12)
 HIV-1 Tat (48-60)
 HIV-1 Rev (34-50)
Amphipathiepeptides
 Penetratin
 pVEC
 Erns
RRL helix
 PRL4
Random eomposition peptides
 Random peptide
RRRRRRRR
RRRRRRRRRRRR
GRKKRRQRRRPPQ
TRQARRNIRRRRWRERQR
RQIKIVVFQNRRMKWKK
LLIILRRRIRKQAHAHSK
RQGAARVTSWLGLQLRIGK
RRLRRLLRRUIUiU.LRRLR
PRLPRLPRIPRL
GLSASPNLQFRTV
A: Alanine, E: Glutamic acid, F: Phenylalanin, G: Glycine, H: Histidine, I: Isoleucine, K:
Lysine, L: Leucine, M: Methionine, N: Asparagine, P: Proline, Q: Glutamine, R: Arginine, S:
Serine, T: Threonine, V: Valine,W: Tiyptophan.
27
2. Materials and methods
2.1. Materials
     Recombinant human insulin (26 IUImg) was purchased from Wako Pure
Chemical lndustries, Ltd. (Osaka, Japan). L-R8, D-R8, L-R12, HIV-1 Tat (48-60), HIV-1
Rev (3450), L-penetratin, D-penetratin, L-pVEC, D-pVEC, L-Erns, L-RRL helix, D-RRL
helix, L-PRL4, and a random peptide (purity År 950/o for each peptide) were purchased
from Sigma-Aldrich Co. (St. Louis, MO, USA). AII other chemicals were of analytical
grade and commercially available.
2.2. Preparation of insulin and CPP solution
     Specific amounts ofrecombinant human insulin were dissolved in 50 pL ofO.l M
HCI in polypropylene tubes. The insulin solution was diluted with 2.4 mL of phosphate
buffered saline (IPBS, pH7.4) containing O.OOIO/o methylcellulose, which prevents the
adsorption of insulin on the tube surface, and normalized with 50 pL ofO.1 M NaOH.
Specific amounts of CPPs were measured in the propylene tubes, and an aliquot of
insulin solution was added to the tubes and mixed gently.
2.3. In situ loop absorption study
     This research was performed at Hoshi University and complied with the
regulations ofthe Committee on Ethics in the Care and Use ofLaboratory Animals, and
was performed in the similar procedures as described in Chapter 1. After the surgical
process, O.5 mL of insulin-CPP solution or insulin solution (control) was administered
directly into the 6 cm ileal loop made from the 10 cm pretreated segment. The dose of
insulin was fixed at 50 IUIkg body weight (132 pM) for all absorption experiments. ln
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the experiments for comparing the absorption enhancement ability ofthe CPPs, the dose
of each CPP was 1.25 pmol!kg (O.5 mM). In dose-dependent experiments with L- and
D-penetratin, the dose was changed to O.125-5 pmol/kg (O.05-2 mM).
     During experiments, a O.25 mL blood aliquot was taken from the jugular vein
before and 5, 10, 15, 30, 60, 120, 180, and 240 min after dosing. Tuberculin syringes (1
mL) were preheparinized in the usual fashion by coating the syringe wall with
aspirating heparin and then expelling all heparin by depressing the plunger to the needle
hub. Plasma was separated by centrifugation at 13,OOO rpm (13,400 Å~ g) for 1 min. The
plasma insulin concentration was determined using an enzyme immunoassay (Insulin
ICMA kit; Molecular Light Technology, Wales, UK). The AUC from O-4 h,
bioavailability relative to the s.c. injection Cmax and Tmax were estimated in the same
procedures as described in Chapter 1.
2.4. LDH leakage
     This examination was performed in the same procedures as described in Chapter
1. After the surgery, a solution ofO.5 mL PBS, 50/o (w/v) sodium taurodeoxycholate, and
L- or D-penetratin (O.5 mM) was administered to the ileum and left in the ileal segments
for 2 h. After the 2 h incubation, the ileal loop was washed with 3 mL PBS and the
intestinal fluid was collected. The concentration of LDH in the fiuid was determined
using the LDH Test Wako (Wako Pure Chemical Industries, Ltd., Osaka, Japan).
2.5. Preparation of the intestinal enzymatic fluid
     Male Wistar rats (200 g) were purchased from Sankyo Lab Service Co., Ltd.
(Tokyo, Japan). Animals were housed in rooms controlled between 23 Å} 1 OC and 55 Å}
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50/o relative humidity, and were allowed free access to water and food during
acclimatization. The rats were fasted for 24 h and anesthetized by i.p. injection of 50
mglkg sodium pentobarbital. The rats were secured to the operating table in a supine
position and a midline abdominal incision was performed. To obtain the intestinal fluid,
a sonde needle was inserted into the upper ponion of the small intestine, and the
intestine was cannulated on the lower side (length = 20 cm) to remove the intestinal
fluid. The contents of the small intestinal were washed out with 30 mL of PBS. This
eMux was treated with two volumes of methylene chloride to remove lipid contents,
which were contained in the intestinal fiuid [54]. The purification was repeated five
times. The total protein concentration of the purified intestinal fluid was determined by
the method ofLowry. The hydrolytic activity ofintestinal enzyme fluid was deterrnined
by measuring the degree of insulin degradation using HPLC as described previously
[55].
2.6. Statistical analysis
     Each value is expressed as the mean Å} standard error (S.E.) of 3-6 determinations.
For group comparisons, analysis of variance (ANOVA) with a one-way layout was
applied. The mean values were evaluated by Student's unpaired t test and p Åq O.05 was
considered significant.
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3. Results
3.1. Effect of CPPs on insulin absorption from the ileum
     No apparent absorption was observed following administration of the insulin
solution in the absence of CPP. Similarly, no apparent insulin absorption was observed
when it was coadministered with seven of the 10 CPPs. These were the L-forms ofR8
                                                                      ,
R12, HIV-Rev, HIV-Tat, Erns, PRL4, and the random peptide (data not shown). In
contrast, the L-forms of penetratin, pVEC, and RRL helix significantly increased
intestinal insulin absorption. Therefore, I chose these CPPs for further evaluation in
terms of stereoisomeric difference. Figure 7 shows the effect of these three selected
CPPs on ileal insulin absorption. In this evaluation, R8 was included because I found
that D-R8 was a strong bioavailability enhancer for insulin and that the effects on insulin
absorption were more pronounced for D-R8 than for D-R6 and D-RIO. When the L- or
D-form of R8 was coadministered with insulin into the ileal loop, D-R8 markedly
enhanced insulin absorption through the ileal membrane compared with L-R8. These
results are consistent with the results shown in Chapter I using R6 as an effective CPP.
In contrast, penetratin, pVEC, and RRL helix showed more significant enhancement of
insulin absorption when coadministered in their L-form (O.5 mM).
     Table 8 summarizes the pharmacokinetic parameters derived from insulin
concentration-time profiles following in situ loop administration of insulin with various
CPPs to the ileal segments. The AUC was derived from the plasma insulin
concentration-time profiles, and relative bioavailability was calculated from data
obtained in the s.c. injection study. Although administration of insulin solution produced
negligible absorption, D-R8, L-penetratin, L-pVEC, and L-RRL helix quickly enhanced
insulin intestinal absorption and markedly increased the Cmax, AUC, and bioavailability,
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which are all related to the extent of insulin absorption. L-penetratin showed the most
significant enhancement effects for ileal insulin absorption among the CPPs used in this
study. Therefore, L-penetratin was used in further investigations regarding toxicity to the
intestinal mucosa and dose-dependent enhancement of insulin absorption.
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Fig. 7. Plasma insulin concentration vs. time profiles following in situ administration of insulin (50
IUZkg) with O.5 mM ofCPPs into ileal segments. Each data point represents the mean Å} S.E. (n=3-6).
A: R8, B: Penetratin, C: pVEC, D: RRL helix. Key: (Å~) insulin-PBS solution; (e) L-peptide; (O)
D-peptide.
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Table 8. Pharrnacokinetic parameters following in situ administration of insulin (50 IUlkg) with
CPPs (O.5 mM) into the ileal segments
Cmax QtUfmL) Tmax (min) AUC (pU ' hlmL) Bioavail abi}ity ("fo)
Insulin solution
 + L-R8
 + D-R8
 + L-Penetratin
 + D-Penetratin
 + L-pVEC
+ D-pVEC
 + L-RRL helix
+ D-RRL helix
 4.9 Å} 1.8
 15.9Å} 13.8
537.4 Å} 261.0
465.6 Å} 50.8 su *
 44.5 Å} 20.2
210.4 Å} 60.7*
 5,1 Å} 2.5
 84.7Å} 4.2kft
322 Å} 14.7
76.3 Å} S4.9
46.7 Å} 36.8
18.3 Å} 6.0
13.3 Å} 1.1
23.3 Å} 6.7
11.3 Å} 1.3
13.3 Å} 1.7
15.0 Å} O.O
13.3 Å} 1.7
 5.7 Å} 2.0
 4.1 Å} O.3
88.1 Å} 49.4
163.8Å}27.2*su
21.2 Å} 9.6
121.4 Å} 44.7
 2.1 Å} O.4
 33.1 Å} 4.6rk sc
 12.1 Å} 5.3
O.2 Å} O.1
O.1 Å} O.O
3.0 Å} 1.7
5.5 Å} O.9su sc
O.7 Å} O.3
4.1 Å} 1.5
O.1 Å} O.O
1.1 Å} O.2AA
O,4 Å} O.2
Data: mean Å} S.E. (n=3-6).
Cmax: the maximum concentration; Tmax: the time to reach the Cmax; AUC: the area under the
curve.
"pÅqO.05, ""pÅqO.O1: Significant difference to corresponding "Insulin solution".
3.2. Biochemical examinations of the ileal membranes following penetratin
administration
     Table 9 shows the results of LDH leakage in the presence ofPBS, L-penetratin or
D-penetratin (O.5 mM) in the ileal loop for 2 h. As shown in Table 9, LDH leakage into
the intestinal lumen after administration ofL- or D-penetratin was negligible and similar
to the PBS-treated segments. In contrast, sodium taurodeoxycholate, the positive control,
significantly increased LDH leakage.
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Table 9. Lactate dehydrogenase (LDH) leakage following PBS, L- and D-
penetration (O.5 mM) or 5 wlvO/o sodium taurodeoxycholate
LDH leakage (U)
PBS
L-Penetratin
D-Penetratin
Sodium taurodeoxycholate
 1.19 Å} O.08
2.97 Å} O.62
 2.16Å} O.29
15.54 Å} 2.07k
Data: mean Å} S.E. (n== 3-5).
'pÅqO.05 against control
3.3. Dose-dependent effects of penetratin on ileal insulin absorption
     Figure 8 shows ileal insulin absorption following the in situ administration of
insulin with various concentrations of L- or D-penetratin, and Table 10 summarizes the
pharmacokinetic parameters derived from the insulin concentration-time profiles. The
physical mixture of insulin and penetratin formed aggregates and precipitated at a
concentration ofmore than O.2 mM penetratin. However, L-penetratin enhanced ileal
insulin absorption in a dose-dependent manner, even in solutions in which precipitation
occurred upon reaching the threshold concentration (over O.5 mM L-penetratin). A
significant linear relationship was observed for the AUC ofthe insulin vs. dose response
to L-penetratin (r = O.784, p Åq O.OOI). The relative bioavailability achieved was 35.40/o
by addition of 2 mM L-penetratin to the insulin solution. In eontrast, although
D-•penetratin also increased ileal insulin absorption in a dose-dependent manner at less
than O.5 mM D-penetratin, this enhancement was diminished in the solution in which
34
precipitation occurred upon reaching the threshold          .concentratlon (over O.5 mM
D-penetratin).
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Fig. 8. Plasma insulin concentration vs. time profiles following in situ administration of insulin (50
IUIkg)with various concentrations of L- or D-penetratin into ileal segments. Each data point
represents the mean Å} S.E. (n==3 or 4). Left: L-penetratin, Right: D-penetratin. Key: ( Å~ ) insulin-PBS
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Table 10. Pharmacokinetic parameters following in situ administration of insulin (50 IUlkg)
various concentrations ofL- or D-penetratin into the ileal segrnents
With
Cmax(uU/mL) Tmax(min) AUC (uU• h/mL) Bioavailability (e/o)
Insulin solution
 + LPenetratin
 O.05 mM
 O.1 mM
 O.2 mM
 0.5 mM
 1mM
 2mM
 + D-Penetratin
 O.05 mM
 O.1 mM
 O.2 mM
 O.5mM
 1mM
 2mM
  4.9 Å} 1.8
  8.1 Å} 2.4
  6.3 Å} 1.6
 110.0Å}21.2-
 620.0 Å} 312,2
1061.5 Å} 198.5*
1416.1 Å} 593.8
 33.3 Å} 9.6
 97.7 Å} 52,7
 146.1 Å} 6e.5
 52.8 Å} 11.5
 10.0Å}2.1
  O.8 Å} O.1
76.3 Å} 54.9
30.0 Å} 15.0
11.7 Å} L7
10.0 Å} O.O
13.3 Å} 1.3
15.0 Å} O.O
23.3 Å} 6.7
15.0 Å} O.0
18.3 Å} 6.0
15.0 Å} 0.0
30.0 Å} O.O
33.8 Å} 9.4
73.3 Å} 46.5
  5.7 Å} 2.0
  9.3 Å} 1.0
  6.8 Å} O.4
 28.5 Å} 4.8*k
 181.9 Å} 106.7
512.8 Å} 145.7A
1049.7 Å} 495.1
 17.3 Å} 9.3
 43.5 Å} 29,1
 60.1 Å} 26.1
 26.6 Å} 4.8**
  8.1 Å} 2.6
  O.9 Å} O.4
 O.2 Å} 0.1
 O.3 Å} O.O
 O.2 Å} O.O
 1,O Å} 02A*
 6.1 Å} 3.6
17.3 Å} 4.9h
35,4 Å} 16.7
 O.6 Å} O.3
 1.5 Å} 1.0
 2.0 Å} O.9
 o.g Å} g.2 su "
 o.3 Å} e.1
 o.o Å} o.o
Data: mean Å} S.E. (n=3 or 4).
Cmax: the maximum concentration; Tmax: the time to reach the Cmax; AUC: the area under the
curve.
"pÅqO.05, "*pÅqO.Ol ; Significant difference to corresponding "lnsulin solution".
3.4. Effect ofintestinal fiuid on the aggregation ofinsulin and penetratin
     Figure 9 shows photographs of a physical mixture solution of insulin (132 pM,
the same concentration as the administration solution) and L- or D-penetratin (1 mM).
Aggregation began immediately after;mixing insulin with L- and D-penetratin, and the
mixed solution became cloudy. The turbidity of the solution did not change over time
and seemed to be stable. However, in the case of the insulin and L-penetratin solution,
the turbidity was quickly diminished by adding intestinal solution, and the solution
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became clear after 60 min, as shown in Fig. 9A. In contrast, the turbidity ofthe insulin
and D-penetratin solution remained after adding intestinal solution even after 60 min, as
shown in Fig. 9B.
A
B
          Oinin 5inin 15 inin 30 min 60 niin
Fig. 9. Effect of intestinal enzyme fluid on precipitation induced by the mixing of insulin (132 pM)
and L- or D-penetratin (1 mM). Top photographs: L-penetratin, Bottom photographs: D-penetratin.
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4. Discussion
     For the strategies using CPPs, covalent binding between therapeutic agents and
permeable peptides is essential, and in many cases, drugs and permeable peptides are
cross-linked in a 1:1 molecular ratio. ln contrast, I proposed an approach using a CPP
without intermolecular crosslinking, and I succeeded in achieving efficient delivery of
insulin from the intestine to the systemic circulation using a typical CPP, oligoarginine.
In this noncovalent delivery approach, the absorption enhancing ability of the CPP may
be dependent on the binding affmity ofthe CPP to insulin, based on electrostatic andlor
hydrophobic interactions. Therefore, this approach required relatively high doses of the
CPP. In this chapter, the effects ofsome CPPs on ileal insulin absorption were examined
to identify functional peptides that enhanced intestinal insulin absorption more
effectively.
     As shown in Table 8, intestinal insulin absorption was significantly enhanced by
R8, penetratin, pVEC, and RRL helix. R8 is an artificial CPP composed of eight
residues of arginine; penetratin is derived from Drosophila Antennapedia homeoprotein;
pVEC is derived from murine vascular endothelial cadherin; and RRL helix is ct-helical
amphipathic model peptide consisting of arginine and leucine. Furthermore, the
pharmacological activity of insulin remained after coadministration with these peptides
because a strong hypoglycemic reaction was observed (data not shown). However, the
effectiveness of the L- and D-forms ofpeptides in enhancing insulin absorption differed
among peptides. In the case of R8, the D-form of the peptide had a stronger ability te
enhance intestinal insulin absorption than the L-form. ln contrast, the other three
peptides exerted effects that were more significant when the L-forms were applied. In
the literature, L- and D-oligomers of arginine have been reported to have similar abilities
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to internalize into a cell [31]. However, the sensitivity ofeach oligomer to peptidase and
protease is quite different, and generally peptides composed ofD--form amino acids are
far more resistant to enzymatic degradation than peptides composed of L-form amino
acids [56,57]. Therefore, in the case of D-R8, its high stability in the presence of
intestinal enzymes may result in the strong enhancement effect on ileal insulin
absorption. In contrast, my results demonstrated that L-penetratin, L-pVEC, and L-RRL
helix enhanced intestinal insulin absorption more strongly than their D-forms.
Furthermore, the ability of L-penetratin to enhance insulin absorption was greater than
that of D-R8, and L-penetratin had the most significant effects on enhancing the
bioavailability of insulin among the peptides used in the present study.
     Meanwhile, in a mixture of CPP and insulin, precipitation was induced in the
solutien at high concentrations of CPPs. Cationic peptides interact with negatively
charged proteins, and consequentially aggregates are formed by electrostatic
neutralization [58]. ln agreement with the literature, when high concentrations of CPPs
were added to an insulin solution in the present experiments, turbidity of the solution
was observed, indicating the formation of aggregates. In the case of penetratin,
aggregation began when L- or D-peptides at a concentration of O.5 mM or more were
added into the insulin solution. Therefore, at a CPP concentration of O.5 mM or more, it
may be difficult to increase insulin absorption because the aggregates have visible size
and may not be able to permeate the intestinal lumen to reach the circulation. I speculate
that the fractions of insulin and CPP that bound to each other but did not form bigger
aggregates contributed to the enhancing effect of L-penetratin on intestinal insulin
absorption.
     As shown in Fig. 8 and Table 10, L- and D-penetratin-enhanced intestinal insulin
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absorption was dependent on the applied penetratin concentration up to O.5 mM. ln
contrast, different effects were observed when L- and D--penetratin were applied at
concentrations over O.5 mM. Although L-penetratin significantly enhanced insulin
absorption at concentrations greater than O.5 mM, the absorption enhancing ability of
D-penetratin decreased at concentrations exceeding O.5 mM. To explain these
phenomena, the formation of aggregates after mixing insulin and penetratin was
examined in the presence of intestinal enzyme fluid. As shown in Fig. 9, L-penetratin
aggregates gradually disappeared in the presence of intestinal fluid, and the solution
became almost clear after 60 min. ln contrast, D-penetratin aggregates remained
throughout the study period even in the presence of intestinal fiuid. This implies that
L-penetratin aggregates were degraded by intestinal enzymes because of the low
resistance ofthe L-form ofthe peptide to enzymatic degradation. On the other hand, the
internalization efficiency of penetratin is retained even when its sequence is partially
modified [59], suggesting that the fractionated penetratin may have internalization
ability. In other words, all amino acid sequences ofpenetratin might not be prerequisite
on the cellular internalization of the peptide, therefore, the enzymatic decomposition
products of L-penetratin may enhance insulin intestinal absorption. In contrast, the
enzymatic decomposition products of L-R8 may not have such effects. ln fact, the
number ofarginine residues in L-R8 is important for the internalization efficiency ofthe
molecule, and the effects ofthis CPP dramatically decrease with the decrease in arginine
residues [31].
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5. Conclllsions
     L-penetratin acted as the most effective bioavailability enhancer for intestinal
insulin among the 10 different CPPs used in the present study. The results of the LDH
leakage study suggested that undesirable toxic effects on the intestinal mucosa were not
caused by administration of L-bpenetratin. These results suggest that L-penetratin has
great potential as a powerfu1 tool for insulin delivery across intestinal absorption
barriers. To evaluate the further potential of penetratin as a bioenhancer, it will be
necessary to examine its effects on the bioavailability ofother peptide and protein drugs
that have different electrical charges in physiological pH. In addition, my results suggest
that the effectiveness of CPPs in enhancing intestinal insulin absorption varies
depending on the binding affinity between insulin and each CPP, the applied
concentration of CPP to insulin, and the chirality of amino acids within each CPP.
Therefore, further study is needed to determine affmity constants between insulin and
CPP molecules and clarify the enhancement mechanisms ofCPPs.
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               Chapter 3
Permeation characteristics of oligoarginine
      through intestinal epithelium
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1. Introduction
     In the previous chapters, I have reported that a typical CPP, oligoarginine,
enhances the intestinal absorption of the peptide drug, insulin. Because oligoarginine
has negligible adverse effects on the intestinal mucosa, it is potentially a safe delivery
system. Moreover, my strategy does not need covalent conjugation between drug and
CPP unlike many approaches in other laboratories. However, the mechanisms
underlying its enhancement of intestinal drug absorption are unknown. In addition,
although some publications refer to the epithelial permeation of CPPs [60-64], there is
no information about the permeation characteristic of CPPs, especially oligoarginine,
through biological intestinal membranes.
     In this chapter, I first evaluated the permeability ofisolated rat intestinal epithelial
membranes to oligoarginine itself under various conditions, including low temperature,
the presence ofheparin, and pretreatment with hyaluronidase, to clarify the permeation
characteristics of oligoarginine across the intestinal epithelial membrane. Beside my
methodology based on physically mixed solution ofdrug and CPP, there is a publication
relevant to method based on covalent binding which achieve the effective insulin
permeation [49]. However, this was undertaken by using Caco-2 cells, not biological
membrane. Therefore, the effects on the biological ileal permeation of a peptide drug
after its coincubation with oligoarginine and the absorption of an
oligoarginine-introduced peptide derivative by ileal segments were examined to
evaluate the usefulness of an oral delivery system based on oligoarginine. Leuprolide, a
relatively small peptide, was used and was conjugated to oligoarginine.
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2. Materials and Methods
2.1 Materials
     Leuprolide acetate salt, L-R6 (RRRRRR; R, L-arginine), D••R6 (rrrm; r,
D-arginine), fluorescein-labeled D-R6 (FL-D-R6), and lyophilized hyaluronidase (EC
3.2.1.35; type IV-S from bovine testes, 56 kDa, 1370 IUImg solid) were purchased from
Sigma-Aldrich Co. (St Louis, MO, USA). Heparin sodium was purchased from Wako
Pure Chemical Industries, Ltd (Osaka, Japan). The leuprolide-D-R6 conjugate (amino
acid sequence shown in Table 11) was synthesized by the Peptide Institute, Inc. (Osaka,
Japan). All other chemicals were of analytical grade and are commercially available.
   Table 11. Molecuiar weights and amino acid sequences of leuprolide and the leuprolide-D-R6
   conJugate
Peptides Mw Sequence
Leuprolide
Leuprolide-D-R6
1209
2636
  xllWSYILRP-NHCH2CH3
XHWSYILRPrrrrrrk(FITC)-NH2
   X: pyroglutamic acid, H: histidine, W: tryptophan, S: serin Y: tyrosine 1: D-leucine, L: leucine,
   R: arginine, P: praline, r: D-arginine k: D-lysine.
2.2. Animals
     Male Wistar rats weighing 180-220 g were purchased from Sankyo Laboratory
Service (Tokyo, Japan). The experiments using animals were performed at Hoshi
University and complied with the regulations of the Committee on Ethics in the Care
and Use ofLaboratory Animals. The animals were housed in rooms maintained at 23 Å}
1 OC and 55 Å} 50/e relative humidity, and were allowed free access to water and food
during acclimatization. All animals were fasted for 24 h before the experiments.
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2.3. In vitro permeation study
     In vitro permeation experiments were performed with an Ussing chamber
(Nihon-Kohden Tokyo, Japan) using rat ileal segments, without Peyer's patches.
2.3.1. FL-D-R6 permeation experiments
     Following anesthetization with an intraperitoneal injection of sodium
pentobarbital (50 mglkg; Dainippon Sumitomo Pharm Co., Ltd., Osaka, Japan), the rats
were restrained in a supine position on a thermostatically controlled board at 37 OC.
Briefly, the ileum was exposed after a small midline incision had been carefu11y made in
the abdomen. lmmediately thereafter, a segment of the ileum was removed, opened
along the mesenteric border, and carefu11y washed with ice-cold (bicarbonate-buffered)
Krebs-Ringer solution (pH 7.4) containing O.OOIO/o methylcellulose to prevent the
adsorption of the peptide to the surface of the chamber or to the container. The
Krebs-Ringer solution contained (in mM): 108.0 NaCl, 11.5 D-glucose, 15.0 NaHC03,
4.7 KCI, 1.8 NaH2P04, O.4 KH2P04, 1.2 MgS04, 1.25 CaC12, 4.9 Na-glutamate, 5.4
Na2-fumarate, and 4.9 Na-pyruvate. The fiattened membrane sheets were then mounted
in an Ussing chamber, exposing a surface area of 1 cm2. Both the mucosal side (donor
side) and the serosal side (receiver side) were filled with 5.0 mL of Krebs-Ringer
solution continuously bubbled with a gas mixture of 950/o 02 and 50/o C02. The
temperature was maintained at 37 or 4 OC during the permeation ofFL-D-R6 across the
ileal membrane. The intestinal membranes were then allowed to equilibrate for 20 min.
FL-D-R6 was prepared with Krebs-Ringer solution. After the equilibration period, the
permeation experiment was started by replacing O.5 mL of the solution on the mucosal
side with an equal volume ofFL-D-R6 solution, and the final concentration on the donor
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side was adjusted to 200 pM FL-D-R6. At a predetermined time, samples (400 pL) were
taken from the serosal side and immediately replaced with an equal volume of
Krebs-Ringer solution. To evaluate the contribution of the adsorption of FL-D-R6 to
cell-surface proteoglycans to the permeation of FL-D-R6 across the ileal mucosal
membrane, FL-D-R6 was coincubated with heparin (1 mglmL) on the donor side. The
permeation experiment was also performed using ileal membrane pretreated with
hyaluronidase to evaluate the contribution of the mucuslglycocalyx layers lying on the
epithelial cells to the ileal perrneation of FL-D-R6. The treatment with hyaluronidase
was perforrned by exposing the ileal segments to 1 .0 mL of hyaluronidase solution (1 .92
Å~ 105 UlmL) dissolved in phosphate-buffered saline (PBS) for 30 min after the intestinal
contents had been flushed out. After exposure, the segments were carefu11y rinsed with
20 mL ofPBS at 37 OC, and the segments were then used in the permeation experiment.
The FL-D-R6 concentration was measured using a microplate luminometer (Mithras
LB940, Berthold Japan, Tokyo, Japan) at excitation and emission wavelengths of 485
and 535 nm, respectively.
The steady-state flux (J,,) was calculated from the linear portion of the cumulative
flux-vs-time curve. The apparent permeability coefficient (P.pp) of each compound vvas
calculated with the equation:
Papp=Jss/C (Eq. 1)
where C is the initial donor concentration.
The amount of tissue-associated FL-D-R6, which is the total amount of the peptide
internalized to the inside of the membrane and the peptide bound to the surface of the
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membrane, was determined by measuring the fluorescence intensity of the homogenate
of the ileal membrane sheet after the in vitro permeation experlment. At the end of the 3
h permeation experiment, the ileal tissue was removed from the Ussing chamber. The
area of the ileal membrane exposed to the solution was excised and rinsed thoroughly
twice with 30 mL of Krebs-Ringer solution to remove any unbound FL--D-R6. The
washed tissue was homogenized with a Tefion homogenizer in fresh Krebs-Ringer
solution, and centrifuged at 200 Å~ g for 1O min at 4 OC to remove any tissue fragments.
The supernatants were analyzed after each centrifugation with a microplate luminometer
at excitation and emission wavelengths of485 and 535 nm, respectively.
2.3.2. Leuprolide permeation experiments
     The ileal segments were removed and treated with the same process as described
above for the FL-D-R6 permeation study. The muscle layers were then stripped away,
and the flat membranes were mounted in an Ussing chamber that exposed O.1 cm2 of
tissue to 1.0 mL ofKrebs-Ringer solution continuously bubbled with 950/o 02-50/o C02
on each side, at 37 OC. The intestinal membranes were then allowed to equilibrate for 20
min. Leuprolide, L-R6, and D-R6 were prepared with Krebs-Ringer solution. After an
equilibration period, the permeation experiment was started by replacing the solution on
the mucosal side with an equal volume of leuprolide and L-R6 or D-R6 solutions, and
the final concentrations on the donor side were adjusted to 125 pM for leuprolide and
125 pM for L-R6 and D-R6. At predetermined times, samples (200 pL) were taken from
the serosal side, and each was immediately replaced with an equal volume of
Krebs-Ringer solution. The leuprolide concentration was measured using a leuprolide
enzyme-linked immunosorbent assay (ELISA) kit (Endocrine Technologies Inc.,
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Fircrest St, Newark, CA, USA).
     To assess tissue viability during the series of experiments, the spontaneous
transmuoosal potential difference (PD) and the short-circuit current (I,,) were monitored
simultaneously at the start and end of each test period. The values for membrane
resistance (Rm) were calculated as PDIIsc, based on Ohm's law. These were corrected by
eliminating the offset voltage between the electrodes and the series fluid resistance,
which was determined before each experiment using the same bathing solutions but
without the membranes mounted in the chamber. The Rm values for the intestinal
membrane in the steady state were greater than 30 9fcm2. The course of Rm during the
test period did not differ in the presence or absence ofR6, indicating that the viability of
the intestinal membrane was maintained in the presence ofR6.
2.4. In situ loop absorption study
     This study was performed in the similar procedures as described in Chapter 1.
After the surgical process, Ieuprolide (O.25 mL) or leuprolide-D-R6 solution (O.25 mL)
at 37 OC was directly administered to an ileal loop (6 cm) made from a rinsed segment
(10 cm). The concentration of both drug solutions was 10 mM, so that the doses of
leuprolide and leuprolide-D-R6 were 12.5 pmollkg body weight. Blood samples (O.3
mL) were withdrawn via the jugular vein before the administration and at 30, 60, 120,
180, 240, 300, and 360 min after the administration of the drug. Additional
intraperitoneal injections of sodium pentobarbital (12.5 mglkg) were necessary every 1
h after the administration of the drug to maintain anesthesia. The plasma was separated
by centrifugation at 13,400 Å~ g for 1 min and kept under refrigeration until analysis. The
efficiency of leuprolide and leuprolide-D-R6 absorption was evaluated by measuring the
48
plasma testosterone concentration because it is difficult to determine the plasma
leuprolide-D-R6 concentration with an enzymatic immunoassay-based system. The
increase in the plasma testosterone concentration is dependent on the increase in the
plasma leuprolide concentration and is thus a biological index of absorbed leuprolide.
These concentrations were determined using the Testosterone ELISA Kit for Rodents
(Endocrine Technologies Inc., Fircrest St, Newark, CA, USA). The total area under the
testosterone concentration curve (AUC) from time O to 6 h was estimated from the sum
of successive trapezoids between each data point.
     To confirm the biological activity of leuprolide-D-R6 compared with
unconjugated leuprolide, Ieuprolide-D-R6, and leuprolide were administered via an i.v.
route. In a similar manner to the in situ absorption study, the ileal segments were gently
rinsed with PBS. Leuprolide (200 pL) or leuprolide-D-R6 solution (200 pL) was
administered via thejugular vein. The concentration ofboth drug solutions was 150 nM,
so that the doses of leuprolide and leuprolide-D-R6 were 150 pmol/kg body weight.
Blood samples (O.3 mL) were withdrawn from the jugular vein before the
administration and at 30, 60, 90, 120, 180, 240, and 300 min after the administration of
the drug. As described above, plasma testosterone levels were determined and the AUC
from time O to 6 h was estimated.
2.5. Statistical analysis
     Each value is expressed as the mean Å} standard deviation (S.D.). For group
comparisons, analysis of variance (ANOVA) with a one-way layout was applied. The
mean values were evaluated by Student's unpaired t test andp Åq O.05 was considered
significant.
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3. Results
3.1. Permeation characteristics of oligoarginine through the ileal membrane
     Figure 1O and Table 12 show the time profiIes ofFL-D-R6 permeation through the
isolated ileal membranes, and the parameters of its permeation and tissue distribution
under various conditions, respectively. At 37 OC, simulating biological conditions,
FL-D-R6 pemieated gradually after a short lag time and its P,pp was 7.26 Å~ 10-8 cm/s.
The peptide that was internalized into the intestinal tissue but did not permeate to the
opposite side was 181 nmollg membrane. At 4 OC, at which temperature
energy-dependent active transport across biological membranes is abolished [65,66],
Papp and the tissue-distributed amount ofFL-D-R6 decreased to O.82 Å~ 10ff8 cm!s and
133 nmollg, respectively. Moreover, these parameters decreased to 1.60 Å~ 1O-8 cmls and
21.7 nmollg, respectively, in the presence ofheparin, which was negatively charged and
used to inhibit the electrostatic binding ofpositive molecules to the negatively eharged
proteoglycans on cell membrane surface. In contrast, these parameters increased slightly
in the presence of hyaluronidase, which was used in the pretreatment to diminish the
glycocalyx layer on the membrane, which functions as one ofmajor permeation barriers
for hydrophilic macromolecules and exogenous pathogens.
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Fig. 10. Time profiles of FL-D-R6 perrneation across rat ileal membranes under various conditions.
A: low temperature (4 OC); B: presence ofheparin; C: pretreatment with hyaluronidase. Each data
represents the mean Å} S.D. (n=3).
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Table 12. Apparent permeability coefficients and tissue distributions of FL-D-R6 during the rat
permeation experiment under various conditions
Apparent permeabMty
coefficieng P, (Å~108 cm/s)
Tissue distributed amount
(nmoVg)
Biological condition (37 OC)
Low temperature (4 OC)
VVith Hepaim
Hyaluronidase pretreatment
7.3 Å} O.4
O,8 Å} O.3-
1.6 Å} 1.0-
12.5 Å} 7.3
181 Å} 26
133 Å} 37
 22Å}8se
240 Å} 31
Data: mean Å} S.D. (n==3).
"pÅqO.05 against "biological condition (37 OC)".
3.2. Effect of oligoarginine on the permeation of leuprolide through the ileal
membrane
     Figure 11 and Table 13 show the time profiles ofleuprolide permeation through
isolated ileal membranes and the permeation parameters, respectively. In these
permeation experiments, Ieuprolide and L- or D-R6 were applied as a physically mixed
solution. However, there was no difference in leuprolide permeation with or without L-
or D-R6.
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Fig. 11. Time profiles of leuprolide permeation through rat ileal membranes
presence of L-R6 or D-R6. Each data represents the mean Å} S.D. (n=34).
in the absence or
Table 13. Apparent permeability coefficients of leuprolide during
the rat ileal permeation experiment in the absence or presence ofL-R6
or D-R6
Apparent permeabMty
coefficient,P. (Å~108cm/s)
Leuprolide solution
+ L-R6
+ D-R6
10.6 Å} O.2
13.3 Å} 2.6
12.1 Å} 1.2
Data: mean Å} S.D. (n=3-4).
3.3. Determination of the biological activity of the leuprolide-D-R6 conjugate
relative to that of the original leuprolide
     The biological activity of leuprolide is expressed in terms of its
testosterone-stimulatory effect. The AUC oftestosterone 6 h after the i.v. administration
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of 150 pmollkg leuprolide was 138.4 Å} 68.8 ng•minlmL (time profiles not shown). In
contrast, the AUC after the i.v. administration of the leuprolide-D-R6 conjugate was
50.0 Å} 28.0 ng•minlmL. Therefore, the relative biological activity of the leuprolide-D-R6
conjugate, which was calculated by dividing the activity of leuprolide-D-R6 by that of
the original leuprolide, was approximately 0.36.
3.4. Intestinal absorption of the leuprolide-D-R6 conjugate
     Figure 12 shows the effect of the conjugation of leuprolide and D-R6 on the
absorption of leuprolide after in situ ileal administration. The amount of absorbed
leuprolide was determined by measuring the resultant testosterone concentration. The
testosterone concentration after the administration of leuprolide-D-R6 was also
corrected with the equation:
                      Cc=CtlR (Eq. 2)
where Ct is the actual plasma testosterone concentration at time t, R is the relative
biological activity of the leuprolide-D-R6 conjugate in the i.v. experiments (O.36), and
Cc is the corrected plasma testosterone concentration after the administration of the
leuprolide-D-R6 conjugate.
     The plasma testosterone concentrations after the administration of leuprolide
showed a response pattern consistent with the single-dose study of leuprolide. The
increase in the plasma testosterone concentration after the ileal administration of
leuprolide was diminished by conjugating D-R6 to leuprolide. Table 14 summarizes the
pharmacokinetic parameters derived from the testosterone concentration-time profiles
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following the in
   .conJ ugate
situ administration of the
to ileal segments. There was
original leuprolide or the leuprolide-D-R6
no significant difference in the AUCs after the
administration ofleuprolide-D-R6 and the administration ofthe original leuprolide.
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Fig. 12. Plasma testosterone concentrations vs time profiles after the in situ application ofIeuprolide
(e) or the leuprolide-D-R6 conjugate (O) to rat ileal segments. The plasma testosterone
concentration after the conjugate was administered was calculated from the actual concentration (t(X)
and its biological activity Each data represents the mean Å} S.D. (n=3).
Table 14. Pharmacological pararneters after the in situ administration ofleuprolide-D-R6
conJugate to rat segments
Cmax
(ng/mL)
Tmax
(min)
AUC
(ng•hlmL)
Leuprolide
Leuprolide-D-R6
conjugate (corrected)
8.3 Å} 2.2
3.8 Å} 2.4
140.0 Å} 34.6
     l120.0 Å} O.O
18.8 Å} 5.6
7.1 Å} 5.2
These parameters were calculated from the time profiles ofplasma testosterone
concentratlons.
Data: mean Å} SD. (n=3).
Cmax: the maximum testesterone concentration, Tmax: the time to reach the Cmax,
AUC: the area under the curve.
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4. Discussion
     In the previous chapters, I demonstrated that the intestinal absorption of insulin, a
peptide drug, was improved by its coadministration with various CPPs into the ileal
loop. My approach, which was to administer a physical mixture of insulin and
oligoarginine, is distinct from the intracellular delivery using a conjugate of the drug
and a CPP used in many laboratories. However, the mechanisms underlying its
enhancement of intestinal drug absorption are unknown. ln addition, there is negligible
information about the permeation characteristics of CPPs through the biological
intestinal membranes. Therefore, the permeation of oligoarginine, used in Chapter 1,
was first examined to obtain the information relevant to mechanisms on the
enhancement of intestinal drug absorption by oligoarginine.
     In this study, the amount ofoligoarginine that permeated to the serosal side and
the tissuet•distributed amount of oligoarginine (the total adsorbed and internalized
oligoarginine) were measured to evaluate its permeation characteristics. FL•-D-R6,
which is six polymerized D-arginines labeled with fluorescein, was used to eliminate the
enzymatic degradation of oligoarginine, because generally peptides composed ofD-form
amino acids are far more resistant to enzymatic degradation than peptides composed of
L-form amino acids [56]. The permeation ofFL-D-R6 was significantly reduced at 4 OC
compared with its permeation at 37 OC (Fig. 10A and Table 12), suggesting that the
internalization of oligoarginine into the cell or its permeation through the intestinal
epithelial membrane is mediated by an energy-dependent transport pathway. The tissue
distribution of FL-D-R6 was only slightly reduced at 4 OC, implying that the distribution
of the peptide is not affected by the reduction in the incubation temperature, indieating
the energy-independent attachment ofFL-D-R6 to the mucosal membrane. Heparin also
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significantly diminished the permeation of FL-D-R6 through and its distribution in the
intestinal membrane (Fig. 10B and Table 12), suggesting that the free FL-D-R6 fraction
was decreased by the binding of negatively charged heparin to FL-D-R6. Consequently,
the electrostatic adsorption of FL-D-R6 to proteoglycans on the epithelial membrane
surface was abolished. These resuks on intestinal biological membranes are consistent
with the results of other studies of cultured cell lines, which showed that the uptake of
CPPs by cells is mediated by their adsorption to the cell surface and their subsequent
internalization via endocytosis. ln contrast, treatment with hyaluronidase, which reduces
the mucuslglycocalyx layer on the intestinal epithelial membrane, slightly increased the
permeability ofthe mucosal membrane and the tissue distribution ofFL-D-R6 (Fig. 1OC
and Table 12). I speculate that the presence of the mucuslglycocalyx layer is not
involved in the permeation of oligoarginine. ln short, little oligoarginine adsorbed to
this layer. Proteoglycans anchored on the cell surface, which remain on the cell surface
after treatment with hyaluronidase, are essential for the permeation of oligoarginine
through the membrane, rather than the muous/glycooalyx layer. However, the release of
internalized oligoarginine across the basal membrane may be difficult even though its
intemalization into the intestinal epithelium is achieved by above-mentioned
mechanisms, because the permeation of FL-D-R6 was far lower than that of 4-kDa
dextran, FD-4 (data not shown). Thus, the internalization ofoligoarginine on the apical
membrane may induce the increased uptake of peptide drug into intestinal epithelium
and contribute to the enhancement of intestinal drug absorption.
     During the submission of my work based on physically mixed solution of drug
and CPP as mentioned above, it became known that permeation of insulin through
intestinal epithelium was improved by conjugating with Tat peptide [49]. However, this
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examination was performed using Caco-2 cells, not biological membrane. Therefore,
the effects on the biological ileal permeation of Ieuprolide, a peptide drug, after its
coincubation with L- or D-R6 and the absorption ofD-R6--introduced peptide derivative
by ileal segments were examined to evaluate the usefulness of an oral delivery system
based on oligoarginine. First, leuprolide was physically mixed with L- or D-R6 and then
applied to the donor side ofthe Ussing chamber, because the ileal absorption of insulin
was enhanced by its coadministration with L- or D-R6 in Chapter 1. However, the
permeation of leuprolide was not affected by L- or D-R6 (Fig. 11 and Table 13). These
results are consistent with results presented in Chapter 1 in that only the intestinal
absorption ofa negatively charged molecule, insulin, was enhanced by coadministration
with oligoarginine, whereas that ofpositively charged IFN-B and neutral FD-4 was not.
This study suggests that positively charged leuprolide does not interact with positively
charged oligoarginine to form an electrostatic complex. I next covalently conjugated
leuprolide to D-R6. However, the absorption of the leuprolide-D-R6 conjugate was
lower than that of the original leuprolide (Fig. 12 and Table 14).I speculated that the
leuprolide-D-R6 conjugate was taken up by the ileal epithelial cells based on the
above-mentioned results of the FL-D-R6 permeation study and other studies of
protein--CPP or DNA--CPP conjugates in intracellular delivery [36,67]. However, the
permeation of the leuprolide-D-R6 conjugate across the serosal membrane was limited
by its high molecular weight and its polarity when conjugated to D-R6. In fact, it has
been reported that internalized CPPs have difficulty escaping to the outside of the cell
[60,61]. It has also been demonstrated that an increase in molecular weight diminished
the permeation of leuprolide via the paracellular pathway, which is the primary route of
leuprolide perrneation [68,69]. As mentioned above, the main route for the permeation
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of leuprolide shifted from the paracellular pathway to the active transcellular pathway
by conjugating it to D-R6. However, the low permeation of the leuprolide-D-R6
conjugate across the serosal membrane limited its final release into the circulation. In
contrast, other studies have indicated that the permeation of Tat-insulin through a
Caco-2 monolayer was higher than that of the original insulin [49]. The discrepancy
between my present results and other published data is attributable to differences in the
permeation characteristics ofthese drugs through the intestinal epithelium. It is possible
that the increased internalization of insulin into epithelial cells resulted directly in the
enhanced permeation to the receiver side because the paracellular transport of insulin is
limited by its molecular weight, which is higher than that of leuprolide (insulin, 5807
Da vs leuprolide, 1209 Da). In contrast, I speculate that insulin physically mixed with
oligoarginine interacts electrostatically with the oligoarginine under the conditions used,
and the complex ofthese molecules enters epithelial cells. The insulin is released from
the complex in the cytoplasm and escapes into the circulation. Thus, the use of a
physically mixed solution of insulin and oligoarginine is considered to be a more
potentially successfu1 and convenient strategy. However, the fact that oligoarginine
enhances intestinal drug absorption, depending on the electrostatic characteristics of
each molecule, has not been demonstrated. It will be necessary to determine the affinity
between oligoarginine and each drug to establish the optimal use of oligoarginine for
intestinal drug delivery.
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5. Conclusions
     This study was undertaken to clarify the permeation characteristics of
oligoarginine through the intestinal epithelial membrane. The internalization of
oligoarginine into the intestinal tissue was mediated by its adsorption to cell-surface
proteoglycans and its subsequent transduction via an energy-dependent pathway. The
release of oligoarginine across basal membrane may be limited, suggesting that the
internalization of oligoarginine on the apical membrane rather than its permeation
through epithelial membrane may contribute to the enhancement of intestinal drug
absorption. AIthough I used a strategy based on the characteristics of oligoarginine to
improve the intestina} permeation of leuprolide, oligoarginine had no stimulatory effect
on the intestinal permeation ofleuprolide either when leuprolide and oligoarginine were
administered together or when an oligoarginine derivative of leuprolide was
administered. The findings of this chapter and previous chapters indicate that the
strategy using oligoarginine to improve intestinal drug permeation requires an
intermolecular interaction, such as an electrostatic interaction, between the drug and
oligoarginine, and in some case a covalent linkage between the macromolecular drug
and oligoarginine may hamper the ability of oligoarginine to enhance intestinal
epithelial permeation oftherapeutic peptides and proteins.
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                      Chapter 4
Importance of intermolecular interactien on the improvement
  of intestinal therapeutic peptide/protein absorption using
                cell-penetrating peptides
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1. Introduction
     In the previous chapters, the sufficient intestinal absorption of therapeutic
peptides and proteins has been achieved by more convenient methods in which a
physical mixture of drug and CPP was administered. This methodology differs from
conventional approaches using CPPs in which a conjugation process between
macromolecules and CPPs is essential for their effective internalization. However, the
reasons why physical mixtures of drug and CPP significantly enhance intestinal drug
absorption are unclear. In a Chpater 1, the effects of the CPP on intestinal drug
absorption were described as different, depending on the physical propenies of the
model drug used. For instance, in an in situ ileal loop absorption study, the ileal
absorption of insulin (a peptide possessing negative charge at physiological pH) was
significantly increased by coadministration of R6; however, the absorption of IFN--B (a
large protein possessing weak positive charge at physiological pH) and neutralized FD-4
was only slightly affected by coadministration of R6. In addition, in an in vitro
pemieation study using isolated rat ileal membrane, the ileal permeation ofleuprolide, a
peptide possessing positive charge, was unchanged in the presence of R6 as shown in
Chapter 3. Thus, only absorption of negatively charged macromolecules was improved
by this methodology, wherein a target molecule was physically mixed with a positively
charged CPP. Therefore, I hypothesized that the electrostatic interaction between each
drug and CPP may be related to the phenomenon whereby the enhancing effect of the
CPP on the intestinal drug absorption varies depending on the kind of drug. Although
the involvement of an electrostatic interaction between CPP and drug to mediate the
enhancing effect ofthe CPP on the drug permeation through cell membranes has been
proposed, until now, there has been no report to provide unambiguous evidence for this
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possibility.
     In this chapter, to verify the electrostatic-interaction hypothesis, I evaluated the
relationship between the ability of the CPP to enhance intestinal drug absorption, and
the intermolecular interaction of drug and CPP. First, the binding characteristics
between D-R8, a typical oligoarginine consisting of only D-form amino acids, and
several peptide drugs possessing different isoelectric points were analyzed by surface
plasmon resonance (SPR)-based measurement. The peptides used in this examination
are shown in Table 15. The effects ofD-R8 on the intestinal absorption ofthese peptide
drugs were examined to clarify the relevance of intermolecular binding. The alteration
ofbinding characteristics between peptide drugs and D-R8 and the consequent changes
in absorption enhancement were evaluated in detail for insulin and glucagon-like
peptide-1 (GLP-1).
        Table 15. Molecular characteristics ofpeptide dmgs used in the present study
Mw pl Polarized amino acids
Gastrin I, Human
Exendin-4
Oxytocin
insulin
GLP-1 (7-3(F)
Leucine Enkephalin
Thyrotropin Releasing Hormone
Angiotensin I
[Arg8]-Vasopressin
Calcitomh, Salmon
Somatostatin
Leuprolide
Luteinizing Hermone-Releasing Hormone
Mastoparan
Adrenocerticotropic Hormone
Dynorphn A porcine
2098
4187
1007
58e8
3298
556
362
1296
1084
3492
1638
1209
1182
1479
2933
2147
2.8
4.5
5.2
5.3
5.5
5.7
7.9
8.0
8.3
g.e
9.2
9.7
9.7
10.9
11.1
11.5
     GIu: 4, Asp: 1
Glu: 5, Asp: 1, Arg: 1, Lys: 2
  Glu: 4, Arg: 1, Lys:1
Glu: 3, Asp: 1, Arg: 1, Lys: 2
  Asp: 1, Arg: 1
     Arg: 1
Glu; 1, Arg: 1, Lys:2
     Lys: 2
     Arg: 1
     Arg: 1
     Lys:3
Glu: 1, Arg: 3, Lys:4
Asp: 1, Arg: 3, Lys:2
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2. Materials and methods
2.1. Materials
     Recombinant human insulin, human gastrin I, angiotensin I, [Arg8]-vasopressin,
luteinizing hormone-releasing hormone (LH-RH), and salmon calcitonin were
purchased from Wako Pure Chemical Industries Ltd. (Osaka, Japan). Exendin-4,
glucagon-like peptide-1 (GLP-1), leucine enkephalin, oxytocin, thyrotropin-releasing
horrnone (TRH), leuprolide acetate salt, somatostatin, mastoparan, adrenocorticotropic
hormone (ACTH) fragment 1-24, dynorphin A, and biotin were purchased from
Sigma-Aldrich Co. (St Louis, MO, USA). D-R8 (rrrrrrrT; r, D-arginine, År900/o purity) and
biotinylated D-R8 (rrrrrrrrc-biotin; c, D-cysteine, År950/o purity) were synthesized by
Sigma Genosys, Life Science Division of Sigma-Aldrich Japan Co. (Ishikari, Japan).
Carboxymethyl dextran (CM5) and Streptavidin (SA)-coated sensorchips were
purchased from GE healthcare UK Ltd. (Buckinghamshire, England). All other
chemicals were of analytical grade and are commercially available.
2.2. Surface plasmon resonance (SPR)-based binding study
     The intermolecular interaction between peptide drugs and CPPs were analyzed by
SPR (Biacore 2000, GE healthcare UK).
2.2.1. Binding of peptides to immobilized CPP
     To measure the binding of peptides to D--R8, biotinylated-D-R8 was first
immobilized to the streptavidin coated on the surface of a SA sensorchip using the
strong interaction between biotin and streptavidin. For the immobilization procedure,
the biotinylated-D-R8 was diluted to a final concentration of 30 pglmL using O.Ol M
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HEPES buffered solution containing O.15 M NaCl and O.O050/o Surfactant P20 (HBS-P,
pH 7.4), (GE healthcare UK) and then immobilized to the surface in separate flow cells
at flow rate of 5 pLlmin. Biotin (30 pglmL) was immobilized to the surface of the
reference flow cell. For binding measurements, different concentrations ofpeptide drugs
(1-200 pM) were injected for 5 min followed by an additional 5 min dissociation phase.
The injections were canied out in HBS-P, pH 6.0 at 20 pLlmin and at 250C. For the
experiments using GLP-1, the injections were canied out in HBS-•P at pH 6.0 and 7.4 to
evaluate the differences arising from pH conditions. At the end of each cycle, the
surface was regenerated by 30 s injeotion of 1 M NaCl.
222. Binding of D-R8 to immobilized insulin
     To measure the binding of D-R8 to insulin, insulin was immobilized at the
carboxymethyl dextran surface of a CM5 sensorchip using amine coupling. For the
immobilization procedure, insulin was diluted to a final concentration of 50 pglmL
using acetate buffer at pH 4.5 and immobilized to the surface in separate flow cells at 10
pL/min for 7 min. The reference surfaces were prepared by amine coupling activation
followed by immediate deactivation. For binding measurements, different
concentrations ofD-R8 (1-100 pM) were injected for 5 min followed by an additional 5
min dissociation phase. At the end of each cycle, the surface was regenerated by 30 s
injection of 1 M NaCl. The measurements were carried out in HBS-P, pH 6.0 at
20 pLlmin and at 250C.
2.2.3. Analysis of binding characteristics between peptide drugs and D-R
     Each sensorgram was shown by subtracting nonspecific binding on the surface of
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the reference flow cell from total binding on the peptide drug or D-R8-immobilized
surface. Hereinafter, the immobilized molecule is referred to as the `ligand', and the
injected molecule is referred to as the `analyte'. At first, the equilibrium binding of each
cycle was calculated by BIAevaluation software, and then the dissociation constant
(KD) and the maximum amount (R..) were calculated using equilibrium amounts
based on fitting by MULTI sofiMrare followed by Scatchard analysis. Moreover, the
maximum binding capacity at the absorption experimental condition (B..) was
calculated by using following equation (Eq. 3).
                Bmax=[L]t'RmaxlLi (Eq•3)
where [L]t is total ligand concentration at absorption experimental condition, and Li is
the amount of immobilized ligand. Furthermore, the bound ([A]b) and unbound ([A]f)
analyte concentration at absorption experimental condition were calculated using
following equations (Eqs. 4 and 5).
               [A]t = [A]f+ B.. • [A]f/ (KD + [A] f) (Eq.4)
                [A]b=[A]t-[A]f (Eq.5)
where [A]t is total analyte concentration. The bound analyte concentration at absorption
experimental condition [A]b was used as index of binding affmity between peptide
drugs and CPPs.
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2.3. Preparation of drug and D-R8 solution
   The specific amounts of peptide drugs or D-R8 were dissolved in
phosphate-buffered saline (PBS, pH 6.0 or 7.4) containing O.OOIO/o methylcellulose,
which prevents the adsorption ofpeptide drugs on the tube surface. For preparing the
insulin solution, the specific amounts of recombinant human insulin were dissolved in
50 pL of O.1 M HCI. The insulin solution was diluted to 2.4 mL of PBS (pH 6.0)
containing O.OOIO/o methylcellulose, and normalized with 50 pL of O.1 M NaOH. The
peptide drug solution and D-R8 solution were gently mixed to be adjusted to specific
concentration. Each drug-D-R8 mixed solution was clear.
2.4. In situ loop absorption study
     This research was performed at Hoshi University and complied with the
regulations ofthe Committee on Ethics in the Care and Use ofLaboratory Animals, and
was performed in the same procedures as described in Chapter 1. After the surgical
process, O.5mL of drug-D•-R8 mixed solution or pure drug solution (control) was
directly administered into the 6 cm ileal loop made from the 10 cm pretreated segment.
The dose ofall peptide drugs was adjusted to 331.1 nmol/kg body weight (132 pM). For
evaluating the effect of D-R8 on the intestinal absorption of peptide drugs, the dose of
D-R8 was 2.5 ptmollkg body weight (1000 pM). For evaluating the dose dependency of
D-R8 on insulin-absorption enhancement, the dose ofD-R8 was variable from O.125 to
6.55 pmollkg body weight (50 to 2620 pM). The pH of drug-D-R8 mixed solution or
pure drug solution (control) was adjusted to 6.0. For the experiments using GLP-1, the
pH ofGLP-1-D-R8 mixed solution or pure GLP-1 solution (control) was adjusted to 6.0
and 7.4 to evaluate the differences arising from different pH conditions.
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     During the experiments, a O.25 mL blood aliquot was taken from the jugular vein
before and at 5, 10, 15, 30, 60, 120, 180, and 240 min after dosing. Tuberculin syringes
(1 mL) were preheparinized in the usual fashion by coating the syringe wall with
aspirating heparin and then expelling all heparin by depressing the plunger to the needle
hub. Plasma was separated by centrifugation at 13,OOO rpm (13,400 Å~ g) for 1 min. The
plasma concentration of peptide drugs was determined using enzyme immunoassay
(EIA) method. An insulin assay kit (Invitron Ltd., Wales, UK), rat GLP-1 ELISA kit
(Wako Pure Chemical Industries Ltd., Osaka, Japan), Gastrin I (human) EIA kit,
Exendin-4 EIA kit, and Calcitonin (salmon) EIA kit (Phoenix Pharmaceuticals Inc.,
Burlingame, CA, USA) were used in the experiments. The AUC from 04 h was
estimated in the same calculations as described in Chapter 1.
2.5. Statistical analysis
     Each value is expressed as the mean Å} standard error (S.E.) of3-5 determinations.
The significance of differences in the mean values was evaluated using Student's
unpaired t test. For multiple comparisons to evaluate the relationship between D-R8
cencentration which bound to insulin and enhancing efficiency ofD-R8 on the insulin
absorption, analysis ofvariance (ANOVA) with Dunnett's test was applied. Differences
were considered significant when thep value was less than O.05.
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3. Results
3.1. Determination of the binding characteristics between peptide drugs and D-R8
     First, the binding of various peptide drugs with different isoelectric points to
immobilized D-R8 was measured using an SPR-based method. Figure 13 A and B show
the sensorgrams obtained in the binding experiments using gastrin or insulin at pH 6.0.
The sensorgram responses increased depending on the injected concentration of these
peptides, therefore, these peptides could be considered to bind to D-R8. In contrast, as
shown in Fig. 13 C and D, the sensorgram responses did not increase when exendin-4 or
calcitonin were injected. Furtherrnore, like exendin-4 or calcitonin, all other peptides
tested would not bind to D-R8 (data not shown). Based on the above-mentioned results,
the binding characteristics between gastrin and insulin and D-R8 were analyzed using
Scatchard plots (Fig. 14 A and D, and B and E, respectively), and the calculated binding
parameters are shown in Table 16. Because the Scatchard plots derived from binding
experiments showed two phase-binding patterns as shown in Fig 14 D and E, KD and
Rmax for both phases were calculated and categorized as high- and low-affinity phases.
By using these values, the bound concentrations of gastrin and insulin in ileal
absorption experiments (the concentrations ofthese peptides and D-R8 are 132 pM and
IOOO pM, respectively) were calculated. As a result of the binding analysis, it was
suggested that the bound gastrin and insulin concentrations were 78.4 pM and 77.5 pM
(59.40/o and 58.70/e oftotal concentration), respectively, and that a large portion ofthese
peptides existed as D-R8 bound form in ileal absorption experiments.
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Table 16. Binding parameters between peptide drugs and immobilized D-R8 derived from the SPR
study
Gastrin (pH6.0)
High Low
 Insulin (pH6.0)
High IJow
G[P-1 (pH7.4)
High Low
Bindingparanieters
  Immobilized D-R8 (pmoVmm2)
  KD (paNd)
  Rmax (RU)
  Rmax (pmollmm2)
  Binding ratio (Peptide/D-R8)
 O.414
 O.865
  12.8
6.09 x lo-S
1.47 x lo-2
 O.414
  112
  172
8.21 x lo'2
 O.198
 O.48S
2.95 x lo-2
  12.2
2,11 x lo-3
4,35 x lo-'
 O.485
9.50 x lo6
3.59 x lo'
6,18 x le3
1.28 x lo`
 O.449
 O.328
  13.9
4,22 Å~ lo-3
9.41 x lo'3
 O.449
  238
  222
6.73 Å~ lo-2
 O.150
In situ abserption experimental
conttitt'en
  Applied peptide pmI)
  App}ied D-R8 an
  Bmax pmI)
  Unbound peptide (IiM)
  Bound peptide (fLM)
  Bound peptide ratio (O/o)
    132
   1000
14.7 198
   53.6
   78.4
   59.4
    132
   1000
4.35 1.28xlO'
    54.5
    77.5
    58.7
    132
   1000
9.41 150
    83.7
    48.3
   36.6
KD (pM) and Rmax (pmoYmm2) values were calculated from the Scatchard plots depicted in Fig. 14.
Binding ratio (PeptidelD-R8) was calculated by dividing Rniax by immobilized D-R8 amount. The
parameters at the in situ absorption experimenta1 condition were calculated using equations 3, 4 and
5 described in the Materials and methods section.
3.2. Effect of D-R8 on the ileal absorption of peptide drugs
     In order to analyze the relationship between the absorption enhancement effect of
D-R8 and the binding characteristics between peptide drugs and D-R8, I administered
gastrin, insulin, exendin-4, or calcitonin into rat ileal loops in the absence or presence of
D-R8. Figure 15 A and B show the effect of D-R8 on the ileal gastrin and insulin
absorption, respectively. No apparent absorption was observed following administration
of gastrin or insulin solution in the absence of D-R8. In contrast, coadministration of
Dny-R8 significantly increased intestinal gastrin or insulin absorption. Figure 15 C and D
show the effect ofD-R8 on the ileal exendin-4 and calcitonin absorption, respectively.
Unlike for gastrin and insulin, the absorption of exendin-4 and calcitonin were not
affected by coadministration ofD-R8. Table 17 shows the AUC derived from the plasma
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concentration of each peptide-time profile, and indicates that the AUCs of only gastrin
and insulin among the four peptides were augmented by coadministration ofD-R8.
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Table 17. AUC following in situ administration ofpeptide dmgs
with D-R8 into ileal segrnents
Control
(ng•bltnL)
+ D-R8 (100e pM)
(ng•h/mL)
Gastrin O.55 Å} O.35 1.11 Å} O.47
Insulin O.88 Å} O.32 10.e2 Å} 1.98*
Exen(lin-4 10.37 Å} 2.70 10.89 Å} 3.12
Calcitonin 2.78 Å} O.79 3.48 Å} O.99
Each value represents the mean Å} S.E. (n = 3-5).
"pÅqO.05, significant difference compared with the corresponding
" control"•
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3.3. Determination of the binding characteristics between GLP-1 and D-R8 at
different pHs
     The binding characteristics between GLP-1 and immobilized D-R8 were
examined at different pHs using an SPR-based method. Figure 16 A shows the
sensorgrams when various concentrations of GLP-1 were injected into a
D-R8-immobilized flow cell at pH 6.0. No apparent increases in sensorgram response
were observed at pH 6.0. In contrast, as shown in Fig. 16 B, the sensorgram responses
increased depending on the injected concentration of GLP-1 at pH 7.4. In addition, the
binding characteristics between GLP-1 and D-R8 at both pHs were analyzed using
Scatchard plots (Fig. 14 C and F), and the calculated binding parameters are shown in
Table 16. The Scatchard plots derived from experiments using GLP-1 showed two
phase-binding patterns as well as the above-mentioned results using gastrin and insulin
as shown in Fig. 14 F, so that KD and Rmax for both phases were calculated and
categorized as high- and low-affinity phases. When these binding parameters are
applied to absorption experiments (concentrations ofGLP-1 and D-R8 were 132 pM and
1000 pM, respectively), the bound concentration ofGLP-1 was 48.3 pM (36.60/o oftotal
concentration).
 S 150
                                  5iso
     -200 O 200 400 600 800 -200 O 200 400 600 800
                Time (sec) Time (sec)
Fig. 16. Binding sensorgrams after injection of various concentrations of GLP-l into an
D-R8-immobilized flow ceil. A: pH 6.0 (1-50 pM). B: pH 7.4 (1-200 pM).
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3.4. Effect of D-R8 on the ileal GLP-1 absorption at different pHs
     Figure 17 A and B show the effect of D-R8 on the ileal GLP-1 absorption
following administration at pH 6.0 and 7.4, respectively. In both cases, the absorption of
GLP-1 was elevated by ceadministration ofD-R8 with GLPd-1. Figure 17 C shows the
AUC derived from the plasma GLP-1 concentration-time profile. The increase of AUC
by coadministration of D-R8 at pH 6.0 was approximately 2.69 fold. In contrast, the
increase ofAUC by coadministration ofD-R8 at pH 7.4 was approximately 6.86 fold.
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3.5. Relationship between applied and bound D-R8 concentrations
     To calculate the concentration ofD-R8 bound to insulin when D-R8 was applied at
various doses in absorption experiments, the binding characteristics between D-R8 and
immobilized insulin were analyzed using an SPR-based method. Figure 18 A shows the
sensorgrams when various concentrations of D-R8 were injected into an
insulin-immobilized flow cell at pH 6.0. The sensorgram responses increased depending
on the injected concentration of D-R8 as well as the when insulin solutions were
inversely injected into a D-R8-immobilized flow cell as shown in Fig. 13 B. In addition,
the binding characteristics between D-R8 and insulin were analyzed using Scatchard
plots (Fig. 18 B and C), and the calculated binding parameters are shown in Table 18.
The Scatchard plots derived from these experiments showed a two phase-binding
pattern as shown in Fig. 18 C, so that KD and R.,. for both phases were calculated and
categorized as high- and low-affinity phases. Moreover, the concentrations of bound
D-R8, when D-R8 was added at various eoncentrations to 132 pM of insulin solution in
the absorption experiments, were calculated. As shown in Fig. 19, the bound D-R8
concentration was augmented depending on the increase of total D-R8 concentration
added to insulin solution.
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Fig. 18. Binding sensorgrams after injection ofvarious concentrations (1-100 pM) ofD-R8 into an
insulin-immobilized flow cell at pH 6.0 (A), and the binding eurve (B) and Scatchard plot (C)
derived from the binding between D-R8 and immobilized insulin (pH6.0). Closed circles:
experimental data, solid 1ines: theoretical data obtained by MULTI fitting.
Table 18. Binding characteristics between D-R8 and
insulin derived from the SPR study at pH 6.0
immobilized
   D-R8
High Low
Immobilized insulin amellnt (pmoVmm2)
KD(pM)
Rmax (RU)
Rmax (pmoUmm2)
Binding ratio (D-R81insulin)
O,269
3.el
 219
0.173
O.641
O.269
44.8
667
O.526
1.96
KD (pM) and R,.,. (pmoUmm2) values were calculated from the
Scatchard plots depicted in Fig. 18, and the binding ratio (D-R81insulin)
was calculated by dividing Rmax by immobilized insulin amount.
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Fig. 19. Relationship between the total D-R8 concentration added to the insulin solution (132 pM)
and the D-R8 concentration bound to insulin. The D-R8 concentration bound to insulin were
calculated using parameters described in Table 18 and equations 3, 4 and 5 described in the Materials
and methods section.
3.6. Relationship between bound D-R8 concentration and absorption-enhancing
efficiency ofD-R8
     To determine the relationship between the bound D-R8 concentration and the
increased efficiency of ileal insulin absorption using D-R8, insulin was coadministered
with various concentrations of D-•R8. Figure 20 A shows the time profiles of plasma
insulin concentrations following the ileal administration of insulin with various
concentrations of D-R8. The insulin absorption was elevated depending on the
coadministered D-R8 concentration. Each concentration of coadministered D-R8 was
converted to the concentration bound to insulin based on Fig. 19, and then the AUC
derived from the plasma insulin concentration-time profile was stated in relation to the
bound D-R8 concentration in Fig. 20 B. The AUC was not augmented at concentrations
less than approximately 200 pM ofbound D-R8. wnen the bound D-R8 concentration
was approximately 250 pM, the AUC was linearly augmented.
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4. Discussion
     My approach using CPPs has achieved significant improvement in intestinal
absorption by coadministration of therapeutic peptides and proteins and CPPs as a
physical mixture, as distinct from the conventional method of using CPPs for
intracellular delivery in which CPPs are covalently linked to drugs and carriers. The
pharmacological activity of therapeutic peptides and proteins may be lost by CPP
conjugation, and the absorption of leuprolide-D-R6 conjugate was not found to be
higher than leuprolide itselfas shown in Chapter 3. Therefore, the conjugation approach
may not favorable for absorption into circulation. In contrast, I have demonstrated that
my approach using a physical mixture does not have such disadvantages and shews
sufficient pharmacological effect as shown in Chapters 1 and 2. It has been
demonstrated that the ability ofa CPP to enhance intestinal drug absorption is different
depending on the kind of drug. Based on the physical properties of drugs, it had been
proposed that the electrostatic interaction between each drug and a positively charged
CPP may be associated with the absorption-enhancing efficiency of CPP
coadministration. However, until now there was no evidence for this link. Therefore, the
present study aimed to elucidate the characteristics of the binding between
macromolecular drugs and CPPs and to establish their relationship with the
absorption-enhancing effect ofCPP coadministration.
     First, various peptide drugs with different isoelectric points, as shown in Table 15,
were used, and the binding characteristics between the drugs and D-R8 and the effect of
coadministration ofD-R8 on drug intestinal absorption were examined. As shown in Fig.
13 A and B, the sensorgram response increased depending on injected peptide
concentration after gastrin or insulin was injected into a D-R8-immobilized flow cell at
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pH 6.0. In contrast, no increase of the sensorgram response was observed after other
peptide drugs including exendin-4 and calcitonin were injected (Fig. 3 C and D, data for
other peptides is not shown). Because gastrin and insulin have low isoelectric points
(Table I5), they are negatively charged at pH 6.0, and so it is proposed that their binding
to positively charged D-R8 was observed. In contrast, most peptide drugs that cannot
bind to D-R8 have high isoelectric points and are positively charged at pH 6.0.
Therefore, it is suggested that no binding was observed between these peptide drugs and
D-R8. However, exendin-4, oxytocin, and a few peptides cannot bind to D-R8 at this pH
despite their low isoelectric points. It is proposed that factors other than electrostatic
characteristics, such as hydrophobicity and teniary structure, may be associated with
intermolecutar interactions between peptide drugs and D-R8. Subsequently, Scatchard
analysis of the binding characteristics between gastrin and insulin and D-R8
demonstrated that the bound concentrations of gastrin and insulin in an in situ loop
absorption experiment (mixture of 132 pM peptide drug and 1000 pM D-R8) were
59.40/o and 58.70/o, respectively (Table 16). Later, the effect ofcoadministration ofD-R8
on the intestinal absorption of these peptide drugs was examined in an in situ loop
absorption study. In this study, gastrin and insulin were used as peptide drugs that bind
to D-R8, and exendin-4 and calcitonin were used as peptide drugs that do not bind to
D-R8. As shown in Fig. 15 A and B and Table 17, the absorption of gastrin and insulin
increased in the presence of D-R8. In contrast, as shown in Fig. 15 C and D and Table
17, the absorption of exendin-4 and calcitonin was not affected by ooadministration of
D-R8. Based on these results, the absorptiont•enhancing effect of coadministration of
drugs and D-R8 corresponds with intermolecular binding between the drug and D-R8,
implying that this binding is an important factor governing the enhancing effect ofD-R8
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on the intestinal absorption ofmacromolecular drugs.
     To elucidate this involvement, the absorption-enhancing effect of D-R8 at
different binding conditions was examined by altering the pH conditions. In this study,
GLP-1 was used as a model peptide drug. As shown in Fig. 16 A, no increase of
sensorgram response was observed after injection of GLP-1 into a D--R8-immobilized
flow cell at pH 6.0. ln contrast, as shown in Fig. 16 B, the sensorgram response
increased depending on the injected GLP-1 concentration after injection of GLP-1 at pH
7.4. It is speculated that charge disposition of GLP-1 weakened at pH 6.0, because the
pH was close to its isoelectric point. In contrast, GLP-1 tended to possess negative
charge at pH 7.4. Therefore, I speculate that the change in charge disposition
contributed to variation in the binding characteristics depending on the pH of the
environment. Moreover, an analysis of the binding parameters between GLP-1 and
D-R8 at pH 7.4 demonstrated that the bound concentration of GLP-1 in an in situ loop
experiment (mixture of 132 pM GLP-1 and 1000 pM D-R8) was 36.60/o (Table 16).
Later, in situ loop absorption experiments were conducted using a physical mixture of
GLP-1 and D-R8 prepared at pH 6.0 or 7.4. As shown in Fig. 17 C, the increases in the
AUC after administration at pH 6.0 and 7.4 were 2.69 and 6.86 fold, respectively. Thus,
a stronger enhancing effect on intestinal GLP-1 absorption was observed after
administration at pH 7.4, at which GLP-1 can strongly bind to D-R8. I propose that the
increase of GLP-1 absorption after administration at pH 6.0, at which GLP-1 cannot
bind to D-R8, was because of a gradual increase of pH in the mixture followed by the
formation of a complex, as the pH of the ileal lumen is intrinsically neutral. Thus, both
the binding efficiency between GLP-1 and D-R8 and the enhancement of intestinal
GLP-•1 absorption were affected by altering the pH of mixture, suggesting that the
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binding characteristics between the drug and D-R8 were associated with the
enhancement of intestinal absorption by D-R8.
     Furthermore, the relationship between the concentration ofD-R8 that bound to the
peptide drug in an in situ loop absorption experiment and the absorption-enhancing
efficiency ofD-R8 were evaluated. In this evaluation, insulin was used as model peptide
drug. To estimate the change in bound D-R8 concentration by altering the concentration
of D-R8 added to insulin, the binding characteristics between D-R8 and immobilized
insulin at pH 6.0 were measured. As shown in Fig. 18 A, the sensorgram response
increased depending on the concentration of injected D-R8 in the above-mentioned
experiment in which insulin was injected into a D-R8-immobilized- fiow cell (Fig. I3 B).
Based on this result, the concentration of D-R8 that bound to insulin in an in situ loop
absorption experiment when various concentrations of D-R8 were mixed with insulin
was estimated by calculating the binding parameters between D-R8 and immobilized
insulin (Table 18). As shown in Fig. 19, the concentration ofD-R8 that bound to insulin
increased following an increase in the D-R8 concentration, but tended to saturate at
approximately 350pM. Subsequently, physical mixtures of insulin and various
concentrations of D-R8 were administered. As shown in Fig. 20 A, augmentation of
intestinal insulin absorption was observed following an increase of mixed D-R8
concentration. Here, to elucidate the relationship between the AUC of insulin and bound
D-R8 concentration, each concentration of mixed D-R8 was converted to the bound
D-R8 concentration, based on the result shown in Fig. 19 (Fig. 20 B). It was found that
the AUC of insulin was not affected in the presence of a bound D-R8 concentration
lower than approximately 250 pM. ln contrast, the AUC of insulin linearly increased
when the bound D-R8 concentration was more than approximately 250 pM. Under these
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conditions ofD-R8-insulin binding, it was noted that the binding ratio between insulin
and D-R8 was approximately 1:2. Therefore, I suggest that the binding of two D-R8
molecules to one insulin molecule is needed to enhance intestinal insulin absorption by
the coadministration of D-R8. Thus, the binding ratio between a drug and CPP obtained
in binding experiments may be an index by which to estimate the dose ofCPP needed to
enhance intestinal absorption. However, the further study may be needed to identify the
accurate binding ratio required to enhance the intestinal insulin absorption, because the
bound D-R8 concentration determined on the SPR-based binding assay may not
completely reflect the interaction behavior in bulk solution due to restricted movement
of insulin by its immobilization on the flow cell.
     The study presented in this chapter demonstrated the importance of
intemiolecular binding between drug and CPP in the strategy ofusing CPPs to enhance
the intestinal absorption of macromolecular drugs. The findings in this study suggest
peptides and proteins whose absorption is possibly improved by coadministration of
CPPs may be screened by measuring the intermolecular binding between drug and CPP,
and it is expected that the optimal use of CPPs as a tool for the intestinal delivery of
therapeutic peptides and proteins will be attained. On the other hand, although D-R8 was
used as model CPP in this study, CPPs have wide diversity and include arginine-rich
and amphipathic peptides. Therefore, I propose that the binding between a drug and a
CPP, such as electrostatic and hydrophobic interactions and hydrogen bonding, is
different depending on the type of CPP. The measuring of binding characteristics
between a drug and various CPPs is needed to determine which CPPs would most
effectively enhance intestinal absorption. ln addition, although it was demonstrated that
the intermolecular binding between a drug and CPP is an important factor in
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intestinal-absorption enhancement, the mechanisms for the uptake of a complex by
epithelial cells and its subsequent release to circulation are not clear. In Chapter 3, I
demonstrated that the absorption of a fusogenic peptide consisting of leuprolide and
D-R6, an oligoarginine, was lower than that ofleuprolide alone. Therefore, it is difficult
for a drug--CPP complex formed via an electrostatic interaction to circulate as an intact
complex. Moreover, in my study using isolated rat ileal membrane shown in Chapter 3,
it was proven that the uptake of D-R6 by ileal epithelial membrane is mediated by the
electrostatic adsorption ofD•-R6 onto cell-surface proteoglycans as the initial process. It
is possible that a drug-CPP complex is dissociated on the cell surface by competitive
interaction between CPP and proteoglycans. In addition, my study shown in Chapter 3
demonstrated that D-R6 adsorbed by proteoglycans was internalized into ileal
epithelium via an energy-dependent pathway, so the complex may be dissociated in
acidic compartments, such as endosomes, after it is taken up by epithelial cells.
Furtherrnore, not only the binding efficiency between a drug and CPP but also other
factors such as the internalization efficiency of the CPP itself may affect
intestinal-absorption enhancement. Thus, although further examination is essential for
understanding the complete mechanisms for the absorption-enhancing effect ofCPPs, to
the best of my knowledge the study presented here is the first reported evidence for a
relationship between intermolecular binding of peptide or protein drugs and CPPs and
the enhancing effect of CPP coadministration on their intestinal absorption. Therefore,
this study may provide information for the development of successfu1 oral delivery
systems for therapeutic peptides and proteins using CPPs.
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5. Conclusions
     The study presented here was conducted to determine the importance of
intermolecular binding between macromolecular drugs and CPPs on the improvement
of the intestinal macromolecular drug absorption using CPPs. I have demonstrated that
coadministration with D-R8 can enhance the intestinal absorption only of peptides that
are able to bind to D-R8. In addition, I have demonstrated that the binding ratio between
insulin and D-R8 is an important factor in enhancing intestinal insulin absorption by
coadministration ofD-R8. Thus, the intermolecular interaction between drugs and CPPs
is related to the efficiency of the absorption-enhancing effect of CPPs on intestinal
macromolecular drug absorption.
84
SUMMARY
     During the past few decades, the biotherapeutic agents such as peptides and
proteins have been contributed to the treatment of several diseases. However, their oral
absorption is significantly limited due to the presence of significant barriers in
gastrointestinal tract, such as enzymatic degradation and mucosal membrane. Therefore,
the feasible approaches are needed for developing the oral forms oftherapeutic peptides
and proteins.
     Meanwhile, recent reports indicated that cell-penetrating peptides (CPPs) such as
HIV-•1 Tat and oligoarginine are considered as a useful tool for the intracellular delivery
of therapeutic macromolecules. Hence, it was expected that the ability of CPPs may be
applicable to enhance the absorption of therapeutic peptides and proteins through
intestinal epithelial membrane. One study suggested that the permeation of insulin
through Caco-2 cell monolayer, which is one of in vitro model intestinal membranes,
was enhanced by crosslinking with HIV-1 Tat peptide [49]. However, there is no
information about improvement of intestinal macromolecular drug absorption using
CPPs on the biological membrane.
     In this thesis, the approach based on physical mixture ofmacromolecular drugs
and CPPs was attempted to actually realize the sufficient intestinal absorption of
therapeutic peptides and proteins. Furthermore, the mechanisms associated with
absorption enhancing effect of CPPs on the intestinal absorption of these drugs were
studied.
     At first, the study presented in Chapter 1 aimed to evaluate whether oligoarginine,
typical CPP, can improve intestinal absorption of insulin in rats. lntestinal insulin
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absorption increased dramatically after coadministration of arginine-hexamer (R6) in a
dose-dependent manner, and the effects on insulin absorption were more pronounced for
D-R6 than for L-R6. Among oligoarginines composed of six, eight, or 10 arginine
residues, D-R8 showed the strongest enhancing effects on insulin intestinal absorption.
In contrast, intestinal absorption ofother model hydrophilic macromolecules, IFN-B and
FD-4, were not affected by coadministration with oligoarginine. Furthermore,
oligoarginine has no untoward effect on the intestinal mucosa. The results shown in
Chapter 1 demonstrate that coadministration of oligoarginine with insulin is more
convenient and safer approach to improve its intestinal absorption without causing
detectable damage in cellular integrity.
     The study presented in Chapter 2 aimed to identify CPPs that are more effective
for the delivery ofinsulin and do not induce toxic effects on the intestine. In this study, I
examined the effects of various types of CPPs inoluding arginine-rich peptides and
amphipathic peptides that aid insulin absorption from rat ileal segments. Among these
peptides, L-penetratin had the strongest ability to enhance intestinal insulin absorption.
Meanwhile, in a physical mixture of CPP and insulin, aggregates formed in the solution
when high concentrations CPPs were present. L-penetratin enhanced insulin absorption
even when administered in an aggregated solution. I then showed that aggregates of
L-penetratin and insulin were broken down in the presence of intestinal degradation
enzymes. Thus, among CPPs used in this study, L-penetratin had the strongest ability to
improve insulin intestinal absorption.
     In Chapter 3, the permeation characteristics of oligoarginine itself across the
intestinal membrane were determined to obtain the information about absorption
enhancement mechanisms. Incubation at low temperature and coincubation with heparin
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reduced the tissue distribution and permeation of FL-D-R6 through the rat ileal
membrane. These results suggest that the attachment of FL-D-R6 to cell-surface
proteoglycans and energy-dependent endocytosis are involved in its permeation through
the ileal epithelial membrane. Based on the characteristics ofoligoarginine, I attempted
to facilitate the intestinal permeation ofthe peptide drug, leuprolide, using the function
of oligoarginine. However, leuprolide permeation was not achieved when leuprolide
was applied with oligoarginine to mucosal side of rat ileal sheets or when a
leuprolideH)ligoarginine conjugate was administered. These findings emphasize that
any strategy using oligoarginine to improve intestinal drug permeation requires an
intermolecular interaction, such as an electrostatic interaction, and a covalent linkage
between the macromolecular drug and oligoarginine may hamper the ability of
oligoarginine to enhance intestinal epithelial permeation of therapeutic peptides and
protelns.
     In Chapter 4, I verified the hypothesis that the electrostatic interaction between
drug and CPP is related to the enhancing effect ofthe CPP on the intestinal absorption
of therapeutic peptides and proteins. Among the 16 peptide drugs possessing different
isoelectric points, it was observed that only gastrin, insulin and GLP-1 bound to D-R8,
and subsequently their intestinal absorption increased by coadministration of D-R8. In
contrast, the intestinal absorption of other peptide drugs that did not bind to D-R8 was
not affected in the presence ofD-R8. Furthermore, as the results of Scatchard analysis
showed, D-R8 increased intestinal insulin absorption when two D-R8 molecules were
bound to an insulin molecule. This study suggests that intermolecular binding between
drug and CPP is an important factor governing the enhancing effect of the CPP on the
intestinal absorption oftherapeutic peptides and proteins.
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     In conclusion, CPPs are likely to become powerfu1 tools for overcoming the low
permeability of therapeutic peptides and proteins through the epithelial cell membrane,
the major barrier to their oral delivery. Further advantage of this promising strategy is
that this successfu1 intestinal absorption could be achieved by more convenient
methodology, coadministration ofCPP with drugs via intermolecular interaction among
them. Hereafter, the further establishment ofdelivery system based on CPPs is required
to realize the development ofthe oral forms oftherapeutic peptides and proteins.
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